



**HAL**  
open science

# Inflammatory blood markers as prognostic and predictive factors for pathological complete response and toxicity in early breast cancer patients receiving neoadjuvant chemotherapy

Iléana Corbeau

## ► To cite this version:

Iléana Corbeau. Inflammatory blood markers as prognostic and predictive factors for pathological complete response and toxicity in early breast cancer patients receiving neoadjuvant chemotherapy. Médecine humaine et pathologie. 2019. dumas-02881076

**HAL Id: dumas-02881076**

**<https://dumas.ccsd.cnrs.fr/dumas-02881076>**

Submitted on 12 Oct 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement

Par

**Iléana CORBEAU**

le 4 Octobre 2019

INFLAMMATORY BLOOD MARKERS AS PROGNOSTIC AND PREDICTIVE  
FACTORS FOR PATHOLOGICAL COMPLETE RESPONSE AND TOXICITY IN  
EARLY BREAST CANCER PATIENTS RECEIVING NEOADJUVANT  
CHEMOTHERAPY

Directeur de thèse : Madame le Dr Séverine GUIU

**JURY**

Président : Monsieur le Professeur Marc YCHOU

Assesseurs :

Madame le Professeur Nadine HOUEDE

Monsieur le Professeur William JACOT

Madame le Docteur Séverine GUIU

UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement

Par

**Iléana CORBEAU**

le 4 Octobre 2019

INFLAMMATORY BLOOD MARKERS AS PROGNOSTIC AND PREDICTIVE  
FACTORS FOR PATHOLOGICAL COMPLETE RESPONSE AND TOXICITY IN  
EARLY BREAST CANCER PATIENTS RECEIVING NEOADJUVANT  
CHEMOTHERAPY

Directeur de thèse : Madame le Dr Séverine GUIU

**JURY**

Président : Monsieur le Professeur Marc YCHOU

Assesseurs :

Madame le Professeur Nadine HOUEDE

Monsieur le Professeur William JACOT

Madame le Docteur Séverine GUIU

**PERSONNEL ENSEIGNANT**

**Professeurs Honoraires**

ALLIEU Yves  
ALRIC Robert  
ARNAUD Bernard  
ASTRUC Jacques  
AUSSILLOUX Charles  
AVEROUS Michel  
AYRAL Guy  
BAILLAT Xavier  
BALDET Pierre  
BALDY-MOULINIER Michel  
BALMES Jean-Louis  
BALMES Pierre  
BANSARD Nicole  
BAYLET René  
BILLIARD Michel  
BLARD Jean-Marie  
BLAYAC Jean Pierre  
BLOTMAN Francis  
BONNEL François  
BOUDET Charles  
BOURGEOIS Jean-Marie  
BRUEL Jean Michel  
BUREAU Jean-Paul  
BRUNEL Michel  
CALLIS Albert  
CANAUD Bernard  
CASTELNAU Didier  
CHAPTAL Paul-André  
CIURANA Albert-Jean  
CLOT Jacques  
D'ATHIS Françoise  
DEMAILLE Jacques  
DESCOMPS Bernard  
DIMEGLIO Alain

DUBOIS Jean Bernard  
DUMAS Robert  
DUMAZER Romain  
ECHENNE Bernard  
FABRE Serge  
FREREBEAU Philippe  
GALIFER René Benoît  
GODLEWSKI Guilhem  
GRASSET Daniel  
GROLLEAU-RAOUX Robert  
GUILHOU Jean-Jacques  
HERTAULT Jean  
HUMEAU Claude  
JAFFIOL Claude  
JANBON Charles  
JANBON François  
JARRY Daniel  
JOYEUX Henri  
LAFFARGUE François  
LALLEMANT Jean Gabriel  
LAMARQUE Jean-Louis  
LAPEYRIE Henri  
LESBROS Daniel  
LOPEZ François Michel  
LORIOT Jean  
LOUBATIERES Marie  
Madeleine  
MAGNAN DE BORNIER  
Bernard  
MARY Henri  
MATHIEU-DAUDE Pierre  
MEYNADIER Jean  
MICHEL François-Bernard  
MICHEL Henri

MION Charles  
MION Henri  
MIRO Luis  
NAVARRO Maurice  
NAVRATIL Henri  
OTHONIEL Jacques  
PAGES Michel  
PEGURET Claude  
PELISSIER Jacques  
POUGET Régis  
PUECH Paul  
PUJOL Henri  
PUJOL Rémy  
RABISCHONG Pierre  
RAMUZ Michel  
RIEU Daniel  
RIOUX Jean-Antoine  
ROCHEFORT Henri  
ROSSI Michel  
ROUANET DE VIGNE LAVIT  
Jean Pierre  
SAINT AUBERT Bernard  
SANCHO-GARNIER Hélène  
SANY Jacques  
SEGNARBIEUX François  
SENAC Jean-Paul  
SERRE Arlette  
SIMON Lucien  
SOLASSOL Claude  
THEVENET André  
VIDAL Jacques  
VISIER Jean Pierre

**Professeurs Emérites**

ARTUS Jean-Claude  
BLANC François  
BOULENGER Jean-Philippe  
BOURREL Gérard  
BRINGER Jacques  
CLAUSTRES Mireille  
DAURES Jean-Pierre  
DAUZAT Michel  
DEDET Jean-Pierre  
ELEDJAM Jean-Jacques  
GUERRIER Bernard  
JOURDAN Jacques

MARES Pierre  
MAURY Michèle  
MILLAT Bertrand  
MAUDELONDE Thierry  
MONNIER Louis  
PREFAUT Christian  
PUJOL Rémy  
SULTAN Charles  
TOUCHON Jacques  
VOISIN Michel  
ZANCA Michel

## Professeurs des Universités - Praticiens Hospitaliers

### PU-PH de classe exceptionnelle

ALBAT Bernard - Chirurgie thoracique et cardiovasculaire  
ALRIC Pierre - Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)  
BACCINO Eric - Médecine légale et droit de la santé  
BASTIEN Patrick - Parasitologie et mycologie  
BONAFE Alain - Radiologie et imagerie médicale  
CAPDEVILA Xavier - Anesthésiologie-réanimation  
COLSON Pascal – Anesthésie-réanimation  
COMBE Bernard - Rhumatologie  
COSTA Pierre - Urologie  
COTTALORDA Jérôme - Chirurgie infantile  
COUBES Philippe – Neurochirurgie  
COURTET Philippe – Psychiatrie d'adultes, addictologie  
CRAMPETTE Louis - Oto-rhino-laryngologie  
CRISTOL Jean Paul - Biochimie et biologie moléculaire  
DAVY Jean Marc - Cardiologie  
DE LA COUSSAYE Jean Emmanuel - Anesthésiologie-réanimation  
DELAPORTE Eric - Maladies infectieuses ; maladies tropicales  
DEMOLY Pascal – Pneumologie, addictologie  
DE WAZIERES Benoît - Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
DOMERGUE Jacques - Chirurgie générale  
DUFFAU Hugues - Neurochirurgie  
DUJOLS Pierre - Biostatistiques, informatique médicale et technologies de la communication  
ELIAOU Jean François - Immunologie  
FABRE Jean Michel - Chirurgie générale  
FRAPIER Jean-Marc – Chirurgie thoracique et cardiovasculaire  
GUILLOT Bernard - Dermato-vénérologie  
HAMAMAH Samir-Biologie et Médecine du développement et de la reproduction ; gynécologie médicale  
HEDON Bernard-Gynécologie-obstétrique ; gynécologie médicale  
HERISSON Christian-Médecine physique et de réadaptation  
JABER Samir-Anesthésiologie-réanimation  
JEANDEL Claude-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
JONQUET Olivier-Réanimation ; médecine d'urgence  
JORGENSEN Christian-Thérapeutique ; médecine d'urgence ; addictologie  
KOTZKI Pierre Olivier-Biophysique et médecine nucléaire  
LANDAIS Paul-Epidémiologie, Economie de la santé et Prévention  
LARREY Dominique-Gastroentérologie ; hépatologie ; addictologie  
LEFRANT Jean-Yves-Anesthésiologie-réanimation  
LE QUELLEC Alain-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
MARTY-ANE Charles - Chirurgie thoracique et cardiovasculaire  
MERCIER Jacques - Physiologie  
MESSNER Patrick – Cardiologie  
MONDAIN Michel – Oto-rhino-laryngologie  
PELISSIER Jacques-Médecine physique et de réadaptation  
RENARD Eric-Endocrinologie, diabète et maladies métaboliques ; gynécologie médicale  
REYNES Jacques-Maladies infectieuses, maladies tropicales  
RIBSTEIN Jean-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
RIPART Jacques-Anesthésiologie-réanimation  
ROUANET Philippe-Cancérologie ; radiothérapie  
SCHVED Jean François-Hématologie; Transfusion  
TAOUREL Patrice-Radiologie et imagerie médicale  
UZIEL Alain -Oto-rhino-laryngologie

VANDE PERRE Philippe-Bactériologie-virologie ; hygiène hospitalière  
YCHOU Marc-Cancérologie ; radiothérapie

**PU-PH de 1re classe**

AGUILAR MARTINEZ Patricia-Hématologie ; transfusion  
AVIGNON Antoine-Nutrition  
AZRIA David -Cancérologie ; radiothérapie  
BAGHDADLI Amaria-Pédopsychiatrie ; addictologie  
BEREGI Jean-Paul-Radiologie et imagerie médicale  
BLAIN Hubert-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
BLANC Pierre-Gastroentérologie ; hépatologie ; addictologie  
BORIE Frédéric-Chirurgie digestive  
BOULOT Pierre-Gynécologie-obstétrique ; gynécologie médicale  
CAMBONIE Gilles -Pédiatrie  
CAMU William-Neurologie  
CANOVAS François-Anatomie  
CARTRON Guillaume-Hématologie ; transfusion  
CHAMMAS Michel-Chirurgie orthopédique et traumatologique  
CHANQUES Gérald – Anesthésie-réanimation  
CORBEAU Pierre-Immunologie  
COSTES Valérie-Anatomie et cytologie pathologiques  
CYTEVAL Catherine-Radiologie et imagerie médicale  
DADURE Christophe-Anesthésiologie-réanimation  
DAUVILLIERS Yves-Physiologie  
DE TAYRAC Renaud-Gynécologie-obstétrique, gynécologie médicale  
DEMARIA Roland-Chirurgie thoracique et cardio-vasculaire  
DEREURE Olivier-Dermatologie – vénéréologie  
DE VOS John – Cytologie et histologie  
DROUPY Stéphane -Urologie  
DUCROS Anne-Neurologie  
GARREL Renaud – Oto-rhino-laryngologie  
HAYOT Maurice - Physiologie  
KLOUCHE Kada-Réanimation ; médecine d'urgence  
KOENIG Michel-Génétique moléculaire  
LABAUGE Pierre- Neurologie  
LAFFONT Isabelle-Médecine physique et de réadaptation  
LAVABRE-BERTRAND Thierry-Cytologie et histologie  
LAVIGNE Jean-Philippe – Bactériologie – virologie, hygiène hospitalière  
LECLERCQ Florence-Cardiologie  
LEHMANN Sylvain-Biochimie et biologie moléculaire  
LE MOING Vincent – Maladies infectieuses, maladies tropicales  
LUMBROSO Serge-Biochimie et Biologie moléculaire  
MARIANO-GOULART Denis-Biophysique et médecine nucléaire  
MATECKI Stéfan -Physiologie  
MEUNIER Laurent-Dermato-vénéréologie  
MOREL Jacques - Rhumatologie  
MORIN Denis-Pédiatrie  
NAVARRO Francis-Chirurgie générale  
PETIT Pierre-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie  
PERNEY Pascal-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
PRUDHOMME Michel - Anatomie  
PUJOL Jean Louis-Pneumologie ; addictologie  
PUJOL Pascal-Biologie cellulaire  
PURPER-OUAKIL Diane-Pédopsychiatrie ; addictologie  
QUERE Isabelle-Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)  
SOTTO Albert-Maladies infectieuses ; maladies tropicales  
TOUITOU Isabelle-Génétique  
TRAN Tu-Anh-Pédiatrie

VERNHET Hélène-Radiologie et imagerie médicale

**PU-PH de 2ème classe**

ASSENAT Éric-Gastroentérologie ; hépatologie ; addictologie  
BERTHET Jean-Philippe-Chirurgie thoracique et cardiovasculaire  
BOURDIN Arnaud-Pneumologie ; addictologie  
CANAUD Ludovic-Chirurgie vasculaire ; Médecine Vasculaire  
CAPDEVIELLE Delphine-Psychiatrie d'Adultes ; addictologie  
CAPTIER Guillaume-Anatomie  
CAYLA Guillaume-Cardiologie  
COLOMBO Pierre-Emmanuel-Cancérologie ; radiothérapie  
COSTALAT Vincent-Radiologie et imagerie médicale  
COULET Bertrand-Chirurgie orthopédique et traumatologique  
CUVILLON Philippe-Anesthésiologie-réanimation  
DAIEN Vincent-Ophtalmologie  
DORANDEU Anne-Médecine légale -  
DUPEYRON Arnaud-Médecine physique et de réadaptation  
FAILLIE Jean-Luc – Pharmacologie fondamentale, pharmacologie clinique, addictologie  
FESLER Pierre-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
GAUJOUX Viala Cécile-Rhumatologie  
GENEVIEVE David-Génétique  
GODREUIL Sylvain-Bactériologie-virologie ; hygiène hospitalière  
GUILLAUME Sébastien-Urgences et Post urgences psychiatriques -  
GUILPAIN Philippe-Médecine Interne, gériatrie et biologie du vieillissement; addictologie  
GUIU Boris-Radiologie et imagerie médicale  
HERLIN Christian – Chirurgie plastique, reconstructrice et esthétique, brûlologie  
HOUEDE Nadine-Cancérologie ; radiothérapie  
JACOT William-Cancérologie ; Radiothérapie  
JUNG Boris-Réanimation ; médecine d'urgence  
KALFA Nicolas-Chirurgie infantile  
KOUYOUMDJIAN Pascal-Chirurgie orthopédique et traumatologique  
LACHAUD Laurence-Parasitologie et mycologie  
LALLEMANT Benjamin-Oto-rhino-laryngologie  
LE QUINTREC Moglie - Néphrologie  
LETOUZEY Vincent-Gynécologie-obstétrique ; gynécologie médicale  
LONJON Nicolas - Neurologie  
LOPEZ CASTROMAN Jorge-Psychiatrie d'Adultes ; addictologie  
LUKAS Cédric-Rhumatologie  
MAURY Philippe-Chirurgie orthopédique et traumatologique  
MILLET Ingrid-Radiologie et imagerie médicale  
MORANNE Olivier-Néphrologie  
NAGOT Nicolas-Biostatistiques, informatique médicale et technologies de la communication  
NOCCA David-Chirurgie digestive  
PANARO Fabrizio-Chirurgie générale  
PARIS Françoise-Biologie et médecine du développement et de la reproduction ; gynécologie médicale  
PASQUIE Jean-Luc-Cardiologie  
PEREZ MARTIN Antonia-Physiologie  
POUDEROUX Philippe-Gastroentérologie ; hépatologie ; addictologie  
RIGAU Valérie-Anatomie et cytologie pathologiques  
RIVIER François-Pédiatrie  
ROGER Pascal-Anatomie et cytologie pathologiques  
ROSSI Jean François-Hématologie ; transfusion  
ROUBILLE François-Cardiologie  
SEBBANE Mustapha-Anesthésiologie-réanimation  
SIRVENT Nicolas-Pédiatrie  
SOLASSOL Jérôme-Biologie cellulaire  
STOEBNER Pierre – Dermato-vénéréologie  
SULTAN Ariane-Nutrition

THOUVENOT Éric-Neurologie  
THURET Rodolphe-Urologie  
VENAIL Frédéric-Oto-rhino-laryngologie  
VILLAIN Max-Ophtalmologie  
VINCENT Denis -Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
VINCENT Thierry-Immunologie  
WOJTUSCISZYN Anne-Endocrinologie-diabétologie-nutrition

### **PROFESSEURS DES UNIVERSITES**

#### 1re classe :

COLINGE Jacques - Cancérologie, Signalisation cellulaire et systèmes complexes

#### 2ème classe :

LAOUDJ CHENIVESSE Dalila - Biochimie et biologie moléculaire

VISIER Laurent - Sociologie, démographie

### **PROFESSEURS DES UNIVERSITES - Médecine générale**

#### 1re classe :

LAMBERT Philippe

#### 2ème classe :

AMOUYAL Michel

### **PROFESSEURS ASSOCIES - Médecine Générale**

CLARY Bernard

DAVID Michel

PROFESSEUR ASSOCIE - Médecine

BESSIS Didier - Dermato-vénéréologie

MEUNIER Isabelle – Ophtalmologie

MULLER Laurent – Anesthésiologie-réanimation

PERRIGAULT Pierre-François - Anesthésiologie-réanimation ; médecine d'urgence

ROUBERTIE Agathe – Pédiatrie

### **Maîtres de Conférences des Universités - Praticiens Hospitaliers**

#### **MCU-PH Hors classe**

BOULLE Nathalie – Biologie cellulaire

CACHEUX-RATABOUL Valère-Génétique

CARRIERE Christian-Bactériologie-virologie ; hygiène hospitalière

CHARACHON Sylvie-Bactériologie-virologie ; hygiène hospitalière

FABBRO-PERAY Pascale-Epidémiologie, économie de la santé et prévention

HILLAIRE-BUYS Dominique-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie

GIANSILY-BLAIZOT Muriel – Hématologie, transfusion

PELLESTOR Franck-Cytologie et histologie

PUJOL Joseph-Anatomie

RICHARD Bruno-Thérapeutique ; addictologie

RISPAIL Philippe-Parasitologie et mycologie

SEGONDY Michel-Bactériologie-virologie ; hygiène hospitalière

#### **MCU-PH de 1re classe**

BADIOU Stéphanie-Biochimie et biologie moléculaire

BOUDOUSQ Vincent-Biophysique et médecine nucléaire

BOURGIER Céline-Cancérologie ; Radiothérapie

BRET Caroline-Hématologie biologique



COSSEE Mireille-Génétique Moléculaire  
GABELLE DELOUSTAL Audrey-Neurologie  
GIRARDET-BESSIS Anne-Biochimie et biologie moléculaire  
LAVIGNE Géraldine-Hématologie ; transfusion  
LESAGE François-Xavier – Médecine et santé au travail  
MATHIEU Olivier-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie  
MENJOT de CHAMPFLEUR Nicolas-Neuroradiologie  
MOUZAT Kévin-Biochimie et biologie moléculaire  
PANABIERES Catherine-Biologie cellulaire  
PHILIBERT Pascal-Biologie et médecine du développement et de la reproduction  
RAVEL Christophe - Parasitologie et mycologie  
SCHUSTER-BECK Iris-Physiologie  
STERKERS Yvon-Parasitologie et mycologie  
TUAILLON Edouard-Bactériologie-virologie ; hygiène hospitalière  
YACHOUH Jacques-Chirurgie maxillo-faciale et stomatologie

**MCU-PH de 2ème classe**

BERTRAND Martin-Anatomie  
DE JONG Audrey – Anesthésie-réanimation  
DU THANH Aurélie-Dermato-vénérologie  
GALANAUD Jean Philippe-Médecine Vasculaire  
GOUZI Farès-Physiologie  
HERRERO Astrid – Chirurgie générale  
JEZIORSKI Éric-Pédiatrie  
KUSTER Nils-Biochimie et biologie moléculaire  
MAKINSON Alain-Maladies infectieuses, Maladies tropicales  
MURA Thibault-Biostatistiques, informatique médicale et technologies de la communication  
OLIE Emilie-Psychiatrie d'adultes ; addictologie  
PANTEL Alix – Bactériologie-virologie, hygiène hospitalière  
PERS Yves-Marie – Thérapeutique, addictologie  
SABLEWSKI Vanessa – Anatomie et cytologie pathologiques  
THEVENIN-RENE Céline-Immunologie

**MAITRES DE CONFERENCES DES UNIVERSITES - Médecine Générale**

**Maîtres de conférence de 1ère classe**

COSTA David

**Maîtres de conférence de 2ème classe**

FOLCO-LOGNOS Béatrice  
OUDE-ENGBERINK Agnès

## **MAITRES DE CONFERENCES ASSOCIES - Médecine Générale**

GARCIA Marc  
MILLION Elodie  
PAVAGEAU Sylvain  
REBOUL Marie-Catherine  
SERAYET Philippe

## **MAITRES DE CONFERENCES DES UNIVERSITES**

### **Maîtres de Conférences hors classe**

BADIA Eric - Sciences biologiques fondamentales et cliniques

### **Maîtres de Conférences de classe normale**

BECAMEL Carine - Neurosciences  
BERNEX Florence - Physiologie  
CHAUMONT-DUBEL Séverine - Sciences du médicament et des autres produits de santé  
CHAZAL Nathalie - Biologie cellulaire  
DELABY Constance - Biochimie et biologie moléculaire  
GUGLIELMI Laurence - Sciences biologiques fondamentales et cliniques  
HENRY Laurent - Sciences biologiques fondamentales et cliniques  
LADRET Véronique - Mathématiques appliquées et applications des mathématiques  
LAINE Sébastien - Sciences du Médicament et autres produits de santé  
LE GALLIC Lionel - Sciences du médicament et autres produits de santé  
LOZZA Catherine - Sciences physico-chimiques et technologies pharmaceutiques  
MAIMOUN Laurent - Sciences physico-chimiques et ingénierie appliquée à la santé  
MOREAUX Jérôme - Science biologiques, fondamentales et cliniques  
MORITZ-GASSER Sylvie - Neurosciences  
MOUTOT Gilles - Philosophie  
PASSERIEUX Emilie - Physiologie  
RAMIREZ Jean-Marie - Histologie  
TAULAN Magali - Biologie Cellulaire

## **PRATICIENS HOSPITALIERS UNIVERSITAIRES**

CLAIRE DAIEN-Rhumatologie  
BASTIDE Sophie-Epidémiologie, économie de la santé et prévention  
GATINOIS Vincent-Histologie, embryologie et cytogénétique  
PINETON DE CHAMBRUN Guillaume-Gastroentérologie ; hépatologie ; addictologie  
SOUCHE François-Régis – Chirurgie générale  
TORRE Antoine-Gynécologie-obstétrique ; gynécologie médicale

## REMERCIEMENTS

A mon président de Jury, Monsieur le Professeur YCHOU :

Merci de me faire l'honneur de présider mon jury de thèse. Malgré toutes vos obligations vous prenez le temps de connaître chacun des internes et vous êtes toujours disponible pour nous voir. Nous avons la chance en Oncologie médicale d'avoir des chefs qui nous épaulent et nous soutiennent, cette attitude est à l'exemple de ce que vous faites pour nous.

Merci pour votre implication humaine, la mise en place d'une soirée d'accueil des internes à chaque semestre et le développement des ateliers de théâtre, qui reflètent votre volonté de pouvoir s'épanouir au travail.

A ma directrice de thèse, le Docteur Séverine GUIU :

Merci infiniment d'avoir accepté de diriger ma thèse et pour ton aide précieuse tout a long de ce travail. On m'avait dit « avant de choisir ton sujet, choisi ton directeur », et je ne l'ai pas regretté une seconde. T'avoir comme directrice a été comme une bouée lors de cette longue traversée ! J'ai beaucoup apprécié que tu me laisses une liberté d'organisation, tout en étant disponible à chaque fois que j'avais besoin de ton aide. A chaque réunion dans ton bureau, alors que j'arrivais dépitée, tu savais tirer le positif, m'encourager et me redonner un nouveau souffle pour repartir.

Merci beaucoup pour tout ce que tu m'as appris auprès des patients et pour ta disponibilité à chaque fois que l'on t'appelle dans les étages. J'ai hâte de pouvoir apprendre à tes cotés en consultation. (S'il te plaît, ne pars pas élever des chèvres, la perte serait trop grande !)

Aux membres du jury,

Au Pr Nadine HOUEDE :

Merci d'avoir accepté de juger ce travail de thèse. J'ai énormément apprécié travailler dans votre service au cours de mon internat. Apprendre auprès de vous a été très enrichissant et j'admire votre sens clinique et les relations que vous entretenez avec vos patients. Merci d'être toujours disponible et à l'écoute de vos internes. Vous êtes pour moi un modèle d'équilibre entre la clinique, la recherche, l'enseignement et la vie personnelle.

Au Pr William JACOT :

William, je ne te remercie pas d'avoir eu l'idée de me faire écrire un article princeps ET une revue de la littérature... mais pour tout le reste, je te suis très reconnaissante. Merci pour ton aide tout au long de ce travail et surtout pour tes relectures, tes corrections et tes conseils dans la rédaction de ce travail.

Merci aussi pour ton implication auprès des internes d'oncologie médicale et ton engagement dans l'enseignement.

A ma famille

A mes grands-pères, que je n'ai peu ou pas connus mais dont je sais qu'ils m'ont transmis des traits de caractère.

A Mamita, vous qui m'avez toujours poussé dans les études et qui avez mis un point d'honneur à ce que vos petites filles réussissent autant que les garçons. Merci pour ces leçons répétées. Je suis admirative de la vie que vous avez eu à élever seule vos enfants, puis à choyer en vacances cette ribambelle de petits enfants.

A Mamie, pour ton soutien et tes prières à chacun de mes concours. Merci d'avoir plaidé ma cause auprès de Dieu. Je suis admirative du temps et de l'énergie que tu passes à aider les gens autour de toi. Tu es un éternel soutien et je regrette de ne pas venir te voir plus souvent à Paris.

A mes parents, merci pour votre soutien tout au long de ces études (même si j'ai choisi cette voie malgré vos mises en garde !) Merci de nous avoir appris que le plus important n'est pas tant la réussite mais plutôt la route (et notamment les voyages !) qui peuvent y mener.

Maman, merci pour ta douceur et ton écoute toujours attentive. Malgré tous tes projets et les activités que tu mènes, tu es toujours disponible pour nos tracas ou nos chagrins. Je suis admirative de tout ce que tu entreprends et réussis. Pense à prendre du temps pour toi aussi !

Papa, le cuisinier hors pair, prêt à faire 4 jours de Tupperware pour les ECN ! Merci infiniment pour ton soutien et tes précieux conseils (toujours faire un peu de sport pour garder l'équilibre, j'ai retenu !!) Tu m'as dit un jour ne pas connaître de médecin femme épanouie, saches aujourd'hui que ta fille l'est, et c'est grâce à toi.

A Maeva. Impossible de résumer en quelques mots notre relation et combien je t'aime et je t'admire. Merci pour ta bienveillance, ton grain de folie et tes conseils avisés. Je réalise oh combien le rôle de grande sœur ne doit pas être facile, alors merci du fond du cœur de m'avoir ouvert la voie et d'être toujours là pour moi.

Merci aussi d'avoir choisi Emmanuel, le meilleur beau-frère que l'on puisse imaginer. Merci Emmanuel de toujours nous faire découvrir de nouvelles régions, activités, plats... Tu me rappelles comme la vie en dehors de l'hôpital est importante.

Merci à tous les deux d'avoir amené Adèle dans nos vies, petite canaille qui nous fait tous craquer.

A Cristo, le rescapé de cette famille de médecin. Je suis tellement fière aujourd'hui de l'homme que tu deviens, continues ta route. Autour du monde ou en tour de France, pas toujours évident de te voir, mais chaque moment partagé n'en est que plus fort. J'espère simplement que l'on pourra continuer à t'appeler chouchou, cricri d'amour, lapin, même après tes 25 ans !

A Brigitte et Didier, merci d'être présents à chaque étape importante. Il me semble loin le temps de votre mariage ! Merci d'avoir fait de moi une marraine, et merci Nicolas de me faire découvrir/redécouvrir des activités à chaque fois que l'on se retrouve.

Aux amis

Aux BEAU : Anadele, Raphael, Victor (ainsi qu'à vos conjoints et enfant), que j'aurai presque pu mettre avec la famille tellement nous avons grandi ensemble. Merci d'être là pour chaque étape importante. J'espère que nos enfants connaîtront la joie que nous avons connue de passer nos WE ensemble petits (même si la route pour Corconne donnait envie de vomir !)

A Martin, le plus vieux copain (le vieux de la vieille !) Merci d'avoir choisi médecine (et pas informaticien, quelle perte ça aurait été !) et merci d'être mon confident à chaque fois qu'il me faut une bonne oreille. Je suis heureuse de ces liens que nous avons pu tisser au fur et à mesure des années, malgré nos différences parfois. Mais qui sait, un jour on voyagera peut-être ensemble à l'autre bout du monde (merci Barbara de l'y initier ;))

Les scouts : Julie, Choupie, Babou, Manon, Palou, Greg et Clément. Merci pour tous ces moments partagés en camps d'abord puis lors de nos retrouvailles. Merci de m'avoir accueillie dans votre « équipe compa ». De Boston à Abidjan, notre amitié ne fait que se renforcer.

Aux femmes qui « pètent au lit » : Caro, Popo, Anne-so, Claire, Elsa, Celine, Diane (et à vos maris) MERCI infiniment de m'avoir accueillie en D4. Moi qui pensais passer seule une année de galère, j'ai découvert les sous-colle/goûter et sous-colles/diner ou encore les sous-colles/petit dej ! Vous êtes des pépites de soleil et chaque WE de retrouvailles est un pur moment de bonheur. Tout paraît simple et beau quand on est avec vous. A quand notre prochain périple style Transsibérien ?!

Aux copines de l'externat (Linnéa, Stéphanie, Claire, Chloé), à toutes nos galères de révisions/exams/stress et stages d'externat. Merci d'avoir été un soutien dans ce long périple.

Les Montpelliérains. Même si vous n'en avez que le nom, vous êtes devenus ma deuxième famille. Je n'aurai jamais cru faire autant de nouvelles rencontres en restant dans ma ville natale pour l'internat. Merci pour tous ces moments partagés : Bretagne, Dordogne, Tanzanie, cap ferret (raté), et surtout pour toutes ces bières partagées, les soirs de semaine, pour couper avec le quotidien. Votre présence m'est INDISPENSABLE.

A Camille Dubart, première rencontre de l'internat... et premiers pleurs partagés ! On en a fait de la route. Je suis fière du médecin que tu es devenue (en plus de la sportive que tu étais déjà !) Martin Marques, merci de ton indulgence lors des sorties sportives, et de me laisser Camille pour des soirées Zouz (non sportives) de temps en temps.

Aux Nounou, couple emblématique, vous pourriez être notre image parentale avec un tout petit peu plus d'organisation ! Mais c'est avec toutes vos histoires de galère qu'on vous aime. Suzy merci pour ta douceur et ton écoute, Nounou merci de me rappeler régulièrement que ma spé est vraiment trop nulle...

A Broty, la plus méchante de toutes les copines, et pourtant tant de temps passé ensemble, c'est bien qu'il doit y avoir quelque chose !

A Marine, parce que sous tes airs de dragons je sais que tu connais les chants de messe aussi bien que moi. Merci de prêter ton copain à mon copain, je te revaudrai ça ;)

A Chris, je sais que je ne peux pas lutter contre toi (et ce n'est pas faute d'avoir essayé par la morsure), mais je suis heureuse que ce soit avec toi qu'Arda passe autant de temps. On peut le dire, tu es un bon match-maker.

A Ouaoua, j'admire ta détermination chaque année pour le « ramdam » (mais stp, ce soir, bois une coupe de champagne !)

A Gaëlle, pour ta motivation sportive infinie, et le peu que tu arrives à m'en faire partager. La pro de la photo, je compte sur toi pour sortir un portrait de moi acceptable un jour ;)

A Célia, la Niçoise qui a aussi participé à mon bonheur avec Arda, merci de m'avoir si bien accueillie dans votre bande !

A Alex et Virigine, toujours en vadrouille, pas évidemment de vous attraper pour un dîner ou un WE, mais les moments partagés sont toujours de bons moments.

A Camille et Léo, merci pour vos cours d'escalade, et d'avoir participé au naked challenge !

Aux Widelins, vous êtes partis si loin, revenez vite (même si Clarensac nous paraît loin aussi), notre chambre d'amis sera toujours libre pour vous après une soirée au Berthom.

Et à tous les copains de l'internat : Kévin, Margot, Max, Mika, Alice et Claire, sans vous ces années n'auraient pas eu le même goût.

Aux ZINZIN : Cécile, Estelle, Emilie, Fabien, Florence, Fred, Gaëlle, John, Kevin, Louise, Mathieu, Marion, Nehrnehr, Nina, Philippine, Pierre, Thibault et Vincent (par ordre alphabétique, sinon Vincent va se vexer). Vous êtes ma bouffée d'oxygène !! Merci pour votre enthousiasme permanent et votre incroyable sens de l'organisation qui nous permettent de faire des WE et vacances toujours plus incroyables. Déguisés, en mer et/ou au bord du Salagou, avec vous le punch et toujours plus fou ! Quel bonheur de voir une nouvelle génération zinzin qui va faire perdurer le rythme zinzin.

Merci aussi à vous d'avoir si bien accueilli Arda (même si vos pratiques l'ont parfois surpris !)

Une mention spéciale à Louise, la femme de ma vie. Ces années de colocation partagées avec toi resteront parmi mes meilleurs souvenirs d'étudiantes. Différentes, et pourtant si proches, tu m'as tellement apporté. Je n'ai qu'un rêve, te voir revenir dans la région.

Au ministère de l'oncologie : Charlotte, Delphine, Ondine et Leticia. Nos dîners sont toujours aussi drôles, bienveillants et pleins de ragots. Merci à Thibault de nous supporter !

Charlotte maintenant que tu as accompli tes souhaits professionnels, n'oublies pas de prendre soin de toi et de ta famille.

Aux barboteurs des swing Jammerz : merci de venir boire des bières avec nous plutôt que de répéter après les cours ! Vous êtes tous de belles rencontres et ces lundis soir sont devenus bien plus sympatiques depuis que l'on vous connaît.

A Karolina, la plus incroyable des copines et des jeunes mamans. Ton énergie et ta force sont incroyables. Tu es un concentré d'amour que Isaac et François ont la chance d'avoir au quotidien. Une révélation amicale, un peu tardive mais qui n'en a été que plus forte.

Merci d'écouter mes tracas ridicules du quotidien (alors que toi tu déplaces des montagnes pour Isaac). J'ai hâte que Isaac soit un peu plus grand pour faire plus de soirées cocktails avec toi !

Aux collègues, qui sont bien souvent devenus des amis :

A l'équipe de (l'ex) MA2 ; et particulièrement l'équipe infirmière qui m'a vu « naître » (non sans douleur) dans le monde de l'oncologie. Merci pour votre temps et tout ce que vous m'avez appris. C'est toujours un plaisir de revenir dans votre service les soirs de garde.

Simon, mon premier co-interne, merci pour ce semestre passé et tout ce que tu m'as appris. A Béne et Marie, mes deux mamans du MA2, merci infiniment pour votre temps, votre écoute et votre aide. Je pense sincèrement pouvoir dire que je n'aurai pas tenu le coup sans votre présence. A Emmanuelle, Fabienne et Thibault, merci de m'avoir accompagnée lors de mes premiers pas en tant qu'interne.

A l'équipe d'hématologie de Perpignan. Même si j'ai probablement passé plus de temps sur une planche à voile qu'en RCP j'ai beaucoup appris (et ris) auprès de vous. A Jordan et Philinne, mes supers co-internes.

A toutes les équipes médicales et para médicales des services d'oncologie médicale de Nîmes, merci pour tous ces moments passés. Particulièrement à Miruna, pour tes tenues de soirées toujours plus belles les unes que les autres.

A l'équipe d'HDJ de Saint Eloi, une vraie petite famille où l'on se sent comme à la maison. Vous faites un travail incroyable auprès des patients, et travailler avec vous fut un plaisir.

Au service de Réanimation Médicale de Lapeyronie et particulièrement aux Dr Machado, au Dr Brunot, au Dr Corne, au Dr Pelle et au Dr Moulaire-Rigollet. A toute l'équipe d'interne (Fanny, Fémie, Cédric, Mélanie, Mathieu, Benoit, Maxime, Yassir et Florian) merci d'avoir rendu toutes ces gardes moins douloureuses !

A l'équipe du B2 : le travail n'est pas toujours facile mais vous faites un très beau travail. A Maryline et Charlotte, les piliers du service qui sont au chevet des malades au quotidien.

A Nelly, je me rappelle encore des consultations où j'étais venue avec toi après ma D4 et de tes conseils avisés et justes sur l'oncologie. Merci d'avoir participé à ce choix et surtout merci pour tout ce que tu m'as transmis dans le service ou entre deux dans les couloirs ! (Ne le prend pas mal mais j'espère quand même ne plus t'avoir en chef d'astreinte... tu attires la foudre !)

A l'équipe du B3 : Christine, Juliette, Mélanie, Souad, Cécilia, Rachel, Emilie, Katie et toute l'équipe para médicale. J'ai adoré travailler avec vous (la preuve j'y suis même revenue !) Merci pour votre dynamisme, bonne ambiance et pour tout ce que vous faites pour les patients. Avec vous le travail d'équipe prend tout son sens. J'ai hâte de revenir à l'ICM pour pouvoir prendre les gouters avec vous, et sinon il y aura toujours les soirées ;).

Une dédicace spéciale à Johana, la meilleure des assistantes médicales, tu es un petit bijou !

A toute l'équipe de radiothérapie de Nîmes. Même si vous vous êtes bien moqués de moi en robocop, j'ai beaucoup aimé travailler avec vous ! Au Dr FARCY-JACQUET, pour tout ce que vous m'avez appris, et pour m'avoir laissé faire mes premières consultations seules (à vos dépendants !)

A Diego, merci de m'avoir recruté pour mon stage de master 2, de toujours répondre aux mails et de m'ouvrir de nouvelles opportunités. Surtout, merci de m'avoir fait découvrir les Dolomites !

A toute l'équipe des CG (et les PM du bureau des stars) : merci de m'avoir initié à la recherche, de m'aider dans toutes mes manips (et face à Excel !!), et de m'avoir prouvé que les chercheurs ne sont pas tous des geeks mal habillés ! Merci à Célestine pour ton aide dans la mise en page de ce travail et dédicace spéciale à Alice (la maman de clozapine) : je n'ai aucun doute sur ton avenir professionnel, tu as l'âme d'une grande chercheuse (même si je connais aussi tes penchants non scientifiques !) Merci pour ton aide au quotidien (et surtout de m'avoir supporté et écouté râler pendant des mois sur cette thèse).

Aux co-internes :

Morgan et Benjamin : tous les trois différents mais on a formé une belle équipe « promo 2014 ». J'ai adoré ce stage partagé au B3 avec vous et j'espère avoir l'occasion de passer encore du temps avec vous, à l'ICM ou autour d'une bière.

Alice, c'est toi qui m'as initié à l'oncologie médicale l'été de ma D4, merci de m'avoir encouragé vers ce choix ! Au-delà de l'onco nous avons la même passion pour les fringues, on a fait de beaux échanges entre la gambette et le closet ! Vivement que tu puisses boire à nouveau !

Quentin, Sophie, Charlotte, Marie et Alexis (promo 2015 en force) ! Soyez indulgents avec moi si je suis votre chef un jour, et j'ai surtout hâte de vous retrouver en tant que co-chefs !

A tous les « vieux », et notamment Alexis (mon interne d'hémato avant d'être co-interne d'onco, tu as participé à mon choix dans cette filière), Julien, Elodie (x2 !) et Morgane.

A tous les jeunes (Nicolas, Jeremy, Stan, Manon) et ceux que je ne connais pas encore assez bien. Bonne route, j'espère toujours être disponible si vous avez besoin de moi.

Et bien sûr à Leticia, mon âme sœur de l'oncologie médicale. Je ne peux que te remercier d'avoir fait ton remord en onco med, tu es un réel coup de cœur pour moi. J'adore nos soirées passées à refaire le monde et j'espère du fond du cœur pouvoir travailler avec toi à l'avenir. Tes patients ont une chance incroyable de t'avoir comme interne, et à partir d'aujourd'hui comme médecin.

A tous les patients que j'ai rencontrés, pour leur courage et leur patience. J'apprends au quotidien auprès d'eux, autant d'un point de vue médical que d'un point de vue humain.



A Ardavan,

Mon amour, mon ami, mon confident et bien sur mon petit shah. Merci pour ta patience, ton soutien, ton écoute et tes massages. Tu es mon refuge dans les mauvaises journées. Tu m'as appris à savoir dire non et à parfois savoir ne rien faire, je ne saurai jamais comment assez t'en remercier. Vivre avec toi est la plus belle chose qui me soit arrivée, j'espère maintenant pouvoir vieillir avec toi (mais fais attention à ne pas casser mes pots de crème anti rides !). D'ici là j'ai hâte de réaliser tous nos projets ensemble. Je t'aime

# Table des matières

PREAMBULE.....	20
Introduction générale.....	21
Article 1: Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy .....	25
ABSTRACT .....	26
INTRODUCTION .....	27
METHODS .....	27
Patients.....	27
Pathological assessments.....	28
Treatments .....	28
Endpoints.....	28
Statistical analysis.....	29
RESULTS.....	29
Patient’s characteristics .....	29
Predictive factors for PCR.....	30
Prognostic factors for RFS .....	30
Prognostic factors for OS .....	31
Sub group analyses.....	31
Predictive factors for febrile neutropenia.....	32
DISCUSSION .....	32
BIBLIOGRAPHY.....	41
Article 2: Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review .....	47
ABSTRACT .....	48
1. INTRODUCTION .....	49
2. MATERIAL AND METHODS .....	50
2.1 Search strategy .....	50
2.2 Study Selection .....	51
2.3 Data extraction .....	51
2.4 Definitions .....	52
3. RESULTS.....	52
3.1 Efficacy.....	52

3.1.1 In early BC.....	52
3.1.1.1 Patients receiving NACT .....	52
3.1.1.1.1 Results on PCR.....	53
3.1.1.1.1.1 Studies including all molecular subtypes .....	53
3.1.1.1.1.2 Studies including only specific molecular subtypes.....	53
3.1.1.1.1.3 Subgroup analyses .....	53
3.1.1.1.2 Results on DFS .....	54
3.1.1.1.2.1 Studies including all molecular subtypes .....	54
3.1.1.1.2.2 Studies including only specific molecular subtypes.....	54
3.1.1.1.2.3 Sub group analyses.....	54
3.1.1.1.3 Results on OS and BCSS .....	54
3.1.1.1.3.1 Studies including all molecular subtypes .....	54
3.1.1.1.3.2 Studies including only specific molecular subtypes.....	55
3.1.1.1.3.3 Sub group analyses.....	55
3.1.1.1.4 Conclusion on NLR as prognosis and predictive factor in patients receiving NACT .....	55
3.1.1.1.5 Results on other IBM.....	59
3.1.1.2 Patients receiving adjuvant treatment.....	59
3.1.1.2.1 Results on DFS .....	63
3.1.1.2.1.1 Studies including all molecular subtypes .....	63
3.1.1.2.1.2 Studies with specific molecular subgroups.....	63
3.1.1.2.1.3 Subgroup analyses .....	63
3.1.1.2.2 Results on OS and BCSS.....	64
3.1.1.2.2.1 Studies including all molecular subtypes .....	64
3.1.1.2.2.2 Studies including specific molecular subtypes.....	64
3.1.1.2.2.3 Subgroup analyses .....	64
3.1.1.2.3 Conclusion on NLR as prognostic factor in patients receiving adjuvant treatment.....	64
3.1.1.2.4 Results on other IBM.....	66
3.1.2 Patients with advanced breast cancer .....	67
3.1.2.1 Results on PFS.....	70

3.1.2.1.1 Studies including all molecular subtypes .....	70
3.1.2.1.2 Studies including only specific molecular subtypes .....	70
3.1.2.2 Results on OS.....	70
3.1.2.2.1 Studies including all molecular subtypes .....	70
3.1.2.2.2 Studies including only specific molecular subtypes .....	70
3.1.2.3 Conclusion on NLR as prognostic factor in patients with advanced breast cancer .....	71
3.1.2.4 Results for other IBM .....	72
3.2 Toxicity .....	72
4. CONCLUSION .....	75
BIBLIOGRAPHY .....	78
Conclusion générale .....	85
SERMENT D'HIPPOCRATE .....	87
PERMIS D'IMPRIMER .....	88

## **PREAMBULE**

Ce travail est constitué de deux articles, soumis pour publications dans « Breast Cancer Research an Treatment » et dans « Critical Reviews in Oncology / Hematology » respectivement. Il est accompagné d'une introduction et d'une conclusion en français.

## Introduction générale

Le cancer du sein est le cancer le plus fréquent et la première cause de décès par cancer chez la femme (1). La mortalité par cancer du sein a diminué ces dernières années. Ceci est expliqué d'une part, par l'amélioration de la prise en charge thérapeutique, et d'autre part, par un diagnostic plus précoce lié au développement du dépistage en France. Plusieurs critères clinico-pathologiques sont utilisés pour déterminer si un cancer du sein est à priori de bon ou de mauvais pronostic, et déterminer si un traitement systémique adjuvant doit être administré (chimiothérapie, hormonothérapie), afin de diminuer le risque de récurrence et de décès. Un facteur pronostique va permettre, en l'absence de traitement, de prédire l'évolution de la maladie en termes de risque de rechute et de décès (survie). Un facteur prédictif va permettre de prédire l'évolution de la maladie sous traitement et d'orienter une décision thérapeutique (réponse, toxicité). Les facteurs pronostiques classiques du cancer du sein sont : l'âge au diagnostic, le type histologique, la taille tumorale, le statut ganglionnaire, le grade histopronostique, la présence d'embolies péri-tumorales, le statut des récepteurs hormonaux, le statut HER2 (Human Epidermal Growth Factor 2) et le Ki67. Indépendamment de leur valeur pronostique, les statuts des récepteurs hormonaux et de HER2 sont des facteurs prédictifs du bénéfice clinique apporté par l'hormonothérapie et les thérapies anti-HER2 comme le trastuzumab.

Il est cependant toujours difficile de pouvoir distinguer avec fiabilité les patients qui auront un vrai bénéfice d'un traitement systémique adjuvant, des patients qui n'auront pas d'amélioration de leur pronostic avec un tel traitement, qui sera par ailleurs potentiellement générateur de toxicité et de surcoût pour la société. La recherche de facteurs pronostiques et prédictifs est donc un enjeu majeur dans cette situation. En situation néoadjuvante il est également indispensable de disposer de facteurs prédictifs de réponse histologique complète, parfois corrélée à la survie notamment dans les cancers du sein triple négatifs et HER2 positifs (2).

Les marqueurs biologiques de l'inflammation, tels que les taux de globules blancs, de lymphocytes, de polynucléaires neutrophiles, de plaquettes ou bien des ratios tels que le ratio de neutrophiles sur lymphocytes (neutrophil to lymphocyte ratio, NLR) ou le ratio de plaquettes sur lymphocytes (platelets to lymphocyte ratio, PLR) pourraient être des

marqueurs pronostiques et / ou prédictifs dans de nombreux cancers, y compris dans le cancer du sein. De nombreuses études ont évalué ces biomarqueurs que ce soit en situation néo-adjuvante, adjuvante ou métastatique mais les résultats divergent (3–9).

Le rôle de l'inflammation dans l'initiation et le développement de cancers est de plus en plus étudié et il a été démontré que, les polynucléaires neutrophiles notamment, y participent à travers leur capacité à favoriser la néo-angiogenèse, à sécréter des métalloprotéines et à activer des facteurs de transcription tels que STAT3 (Signal Transducer and Activator Transcription 3) (10–15).

Dans ce travail de thèse nous nous sommes intéressés à ces marqueurs biologiques de l'inflammation et leur potentiel rôle en tant que marqueur pronostique et / ou prédictif de réponse à la chimiothérapie ou de risque de toxicité chimio-induite, et notamment le risque de neutropénie fébrile.

Nous vous présentons ici deux articles. Le premier est une étude rétrospective, sur une population de patientes présentant un cancer du sein localisé traitées à l'Institut du Cancer de Montpellier, ayant reçu une chimiothérapie néoadjuvante entre 2005 et 2013. Nous avons évalué si les différents marqueurs biologiques de l'inflammation cités ci-dessus pouvaient être : des facteurs pronostiques de survie (survie sans progression et survie globale), des facteurs prédictifs de la réponse histologique après chimiothérapie ou des facteurs prédictifs du risque de neutropénie fébrile.

Le deuxième article est une revue exhaustive de la littérature portant sur le NLR en tant que facteur pronostique et / ou prédictif dans le cancer du sein. La première partie collige les différents articles étudiant le NLR en tant que facteur pronostique. Nous avons différencié les articles portant sur les cancers du sein localisés (recevant une chimiothérapie néoadjuvante d'une part et un traitement adjuvant d'autre part), des articles portant sur les cancers du sein métastatiques. Nous avons également comparé les différents articles évaluant le NLR comme facteur prédictif de réponse histologique après chimiothérapie néoadjuvante. Enfin la dernière partie de ce second article rapporte les différents articles étudiant le NLR en tant que facteur prédictif de toxicité de la chimiothérapie.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394–424.
2. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet Lond Engl*. 2014 Jul 12;384(9938):164–72.
3. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. *FEBS Open Bio*. 2015;5:502–7.
4. Faria SS, Fernandes PC, Silva MJB, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedalscience*. 2016;10:702.
5. Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. *OncoTargets Ther*. 2016;9:5567–75.
6. Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res BCR*. 2017 05;19(1):2.
7. Liu X, Qu J-K, Zhang J, Yan Y, Zhao X-X, Wang J-Z, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. *Medicine (Baltimore)*. 2017 Nov;96(45):e8101.
8. Ou Q, Cheng J, Zhang L, Wang H, Wang W, Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? *Tumour Biol J Int Soc Oncodevelopmental Biol Med*. 2017 Jun;39(6):1010428317706214.
9. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. *Medicine (Baltimore)*. 2018 Dec;97(49):e13340.
10. Mouchemore KA, Anderson RL, Hamilton JA. Neutrophils, G-CSF and their contribution to breast cancer metastasis. *FEBS J*. 2018;285(4):665–79.
11. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. *Cell*. 2010 Mar 19;140(6):883–99.
12. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity*. 2019 Jul 16;51(1):27–41.
13. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*. 2009 Jul;30(7):1073–81.



14. Swierczak A, Mouchemore KA, Hamilton JA, Anderson RL. Neutrophils: important contributors to tumor progression and metastasis. *Cancer Metastasis Rev.* 2015 Dec;34(4):735–51.
15. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer.* 2016 Jul;16(7):431–46.

## **Article 1**

**Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy**

**Evaluation des marqueurs biologiques de l'inflammation en tant que facteurs pronostiques et prédictifs chez les patientes recevant une chimiothérapie néoadjuvante pour un cancer du sein localisé.**

Iléana CORBEAU, Simon THEZENAS, Aurélie MARAN-GONZALES, Pierre-Emmanuel COLOMBO, William JACOT, Séverine GUIU

## ABSTRACT

**Purpose:** Inflammatory blood markers such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been reported as putative prognostic factor for survival and predictive factor for pathological complete response (PCR) and toxicity in cancers, however with conflicting results.

**Methods:** We retrospectively analyzed data of 280 patients with early breast cancer receiving neo-adjuvant chemotherapy between 2005 and 2013 in our center. Neutrophil count, lymphocyte count and platelet count before treatment were collected as well as data on PCR, toxicity, recurrence and survival. Univariate and multivariate analyses were performed using a logistic regression model.

**Results:** In multivariate analysis, high PLR was found to be an independent prognostic factor for relapse-free survival (Hazard Ratio [HR] = 1.91; 95%CI = 1.15-3.16;  $p = 0.012$ ) and shorter overall survival (HR = 1.83; 95%CI = 1.03-3.24;  $p = 0.039$ ). NLR was an independent predictive factor for febrile neutropenia (HR = 0.28; 95%CI = 0.13-0.58;  $p = 0,001$ ). No inflammatory blood marker was found to be predictive for PCR in the overall population, however when focusing on triple negative breast cancer molecular subtype, low white blood cell count (< 6.75 G/L) was predictive for a higher PCR rate (Odds ratio [OR] = 0.29; 95%CI = 0.14-0.61;  $p < 0.01$ ).

**Conclusion:** In the present study, PLR was found as an independent prognostic factor for survival, while NLR was an independent predictive factor for febrile neutropenia. These results, if confirmed in prospective studies, could help tailoring treatment and supportive care in clinical routine practice considering their daily routine biological analysis nature.

**Keywords:** breast cancer, neoadjuvant chemotherapy, inflammatory blood marker, predictive factor, prognostic factor, pathological complete response

## INTRODUCTION

Breast cancer (BC) is the most common feminine cancer (with over 2 million new cases worldwide in 2018) and the leading cause of cancer-related death in women (1). Although more and more patients undergo BC treatment, the mortality rate has decreased in developed countries due to improvement in treatments and early detection. Today's challenge is not only to cure these patients but also to reduce treatment-related toxicity.

Neo-adjuvant chemotherapy (NACT) has increasingly become used in early breast cancer (EBC) treatment, especially for patients with Her2 positive or triple negative breast cancer (TNBC). It allows the evaluation of the pathological response to chemotherapy, which has been shown to be correlated with survival (2) since patients achieving pathological complete response (PCR) are showing improved OS and RFS (3,4).

Inflammatory blood markers (IBM) have emerged as potential prognostic factors for survival in different types of cancers including BC, as well as predictive factors for histological response after NACT (5–11). IBM include leucocyte count, lymphocyte count, neutrophil count, and ratios such as platelet to lymphocyte ratio (PLR) or neutrophil to lymphocyte ratio (NLR), the last one being the most evaluated. Several studies have been published on IBM as predictive for PCR in EBC patients receiving NACT, however with conflicting results (12,13).

In the present study, we evaluated if IBM are prognostic for relapse-free survival (RFS) and / or overall survival (OS) in a large series of homogeneously treated EBC patients receiving sequential anthracycline – taxane NACT, and if these IBM are predictive for PCR in the same population of patients. We also evaluated if there was a correlation between IBM and NACT-related toxicity.

## METHODS

### Patients

Patients treated with NACT for an EBC in our institution between January 2005 and September 2013 were included in a clinico-pathological database (14–16). The database follow-up has been updated and completed until March 2019. Patients included in our study presented with unilateral, unifocal, non-metastatic EBC confirmed by core needle biopsy and had received sequential anthracycline – taxane NACT. Initial blood samples were collected before starting

any treatment. Patients without available initial blood sample analysis were excluded from the present study.

### Pathological assessments

Hormone receptor positive BC were defined as tumors with  $\geq 10\%$  of estrogen and/or progesterone receptors immunohistochemical (IHC) expression. Her2 positive BC were defined as tumors with Her2+++ on IHC staining or tumors with IHC Her2++ expression and average HER2 gene copy numbers  $\geq 6$  at cases with a HER2/CEP17 ratio of less than 2 or a HER2/CEP17 ratio of 2 or more, independently of the average gene copy number after fluorescent *in situ* hybridization (FISH) (17).

### Treatments

All patients received three to four cycles of anthracycline-based chemotherapy, followed by three to four cycles of taxane (weekly paclitaxel or docetaxel every 3 weeks). Patients with Her2 positive tumors received neoadjuvant trastuzumab concomitantly with taxane, followed by adjuvant trastuzumab for a total of 12 months. Patients with hormone receptor positive received adjuvant hormone therapy for 5 years. All patients received adjuvant radiation therapy according to ESMO guidelines (18).

### Endpoints

PCR was defined as absence of invasive cancer in the breast and axillary nodes, irrespective of the presence of *in situ* ductal carcinoma (ypT0/is ypN0). RFS was defined as the time from the date of biopsy to the date of documented relapse (local, loco-regional or distant recurrence) or death for progression. OS was defined as the time from the date of biopsy to the date of documented death from any cause.

For the toxicity endpoint, febrile neutropenia (FN) was defined as temperature  $\geq 38.5^\circ$  and neutrophil count  $\leq 0.5$  G/L (19).

As no standard definition of relevant IBM is available, different cut-offs for NLR and PLR were tested. First, a cut-off was set using receiver operating characteristic (ROC) curves, a second one was based using the cut-offs previously published (20–25). We also calculated a cut off for NLR to be statistically associated with a risk of FN.

## Statistical analysis

Descriptive analyses were performed using median and range for continuous parameters, frequency and percentage for categorical variables.

Baseline characteristics of included patients were compared by Kruskal-Wallis tests or Wilcoxon for continuous variables, or chi<sup>2</sup> or Fisher exact test for categorical variables.

The median follow-up was calculated using the reverse Kaplan-Meier method with its confidence interval (CI) of 95%. All event free survival (RFS, OS) were estimated using the Kaplan-Meier method, and then described using medians and rates with their associated 95% CI.

Survival curves were drawn, and the log-rank test was performed to assess differences between groups.

Moreover, multivariate analyses were carried out using logistic regressions or Cox's proportional hazards regressions, with a stepwise selection procedure, to investigate known predictive or prognostics factors respectively.

Odds ratios (OR) and hazard ratios (HR) with their 95% CIs are presented to display reductions of risk.

ROC curves were used to discriminate the optimal threshold for individual marker (NLR / PLR) calculated to maximize the Youden's index (gold standard: relapse).

All P values reported are two sided, and the significance level was set at 5% ( $p < 0.05$ ).

Statistical analysis was performed using the STATA 13.1 software (Stata Corporation, College Station, TX, USA).

## RESULTS

### Patient's characteristics

Two hundred and eighty patients were included in the present study. The median age at diagnosis was 50.3 years old and 36.8% of our patients were menopausal at diagnosis. Clinical stage was mainly cT2 (58.9%) and half of the patients (51.8%) had clinical lymph node invasion. Majority of patients were affected by an invasive ductal carcinoma (84.0%) and histological grade 3 disease (52.2%). One hundred and twenty-seven patients (45.4%) had hormone receptor positive / Her2 negative BC, 41 patients (14.6%) had hormone receptor positive /

Her2 positive BC, 40 patients (14.3%) had hormone receptor negative / Her2 positive BC and 72 patients (25.7%) had TNBC. Eleven patients (6.3%) were known to be *BRCA* 1 or 2 deleterious mutation carriers.

Before any treatment, median white blood cell count was 6.8 G/L, median lymphocyte count was 1.9 G/L, median neutrophil count was 3.9 G/L, median NLR was 2.0 and median PLR was 132.3. Patients' clinical and biological characteristics are summarized in Table 1.

Ninety-one percent of the patients completed the planned NACT sequence. Main causes of interruption were toxicity (3.9%) and progression (1.4%). Seventy percent of the patients had breast-conserving surgery and 98.9% had lymph node surgery. Ninety-seven percent of patients received adjuvant radiation therapy, 55.7% of patients received adjuvant hormone therapy (for reminder 60% of patients were affected by a hormone receptor positive BC) and 27.9% received neoadjuvant / adjuvant trastuzumab (28.9% had Her2 positive BC).

Cut-offs for NLR and PLR calculated using ROC curves gave 2.4 and 131.1 cut-off values, with AUC-ROC values of 0.55 and 0.58 respectively. These cut-offs were not associated with any significant predictive or prognostic value (except for PLR and RFS but only in univariate analysis) (data not shown). Therefore, we used previously published cut-offs for NLR and PLR at 2 and 150 respectively, according to the literature (20–22,26–28).

#### Predictive factors for PCR (Table 2)

Seventy-four patients (26.4%) patients reached PCR. In univariate analysis, histological grade ( $p = 0.001$ ), mitotic index ( $p = 0.006$ ), hormone receptor expression ( $p < 0.001$ ) and molecular subtype ( $p < 0.001$ ) were correlated with PCR. None of the IBM was significantly correlated to PCR. In multivariate analysis, nodal status (OR = 0.43; 95%CI = 0.23-0.82;  $p = 0.01$ ), histological grade (grade 2: OR = 0.13; 95%CI = 0.07-0.27;  $p < 0.01$  and grade 3: OR = 0.28; 95%CI = 0.12-0.63;  $p < 0.01$  versus grade 1) and molecular subtype (hormone receptor positive / Her2 positive: OR = 7.98; 95%CI = 0.12-0.63;  $p < 0.01$ ; hormone receptor negative / Her2 positive: OR = 11.94; 95%CI = 4.76-29,91;  $p > 0.01$  and hormone receptor negative / Her2 negative: OR = 4.65; 95%CI = 1.98-10.89;  $p < 0.01$ ; compared to hormone receptor positive / Her2 positive) were independent predictive factors of PCR.

#### Prognostic factors for RFS (Table 3)

With a median follow-up of 6.7 years (range 0.2 to 11.3) at the date of data cleaning (March 2019), 65 patients (23.2%) had relapsed, including 51 patients with metastatic relapse and 14 patients with locoregional relapse.

Higher cT stage ( $p = 0.005$ ), inflammatory BC ( $p = 0.003$ ), hormone receptor negative BC ( $p = 0.003$ ), TNBC ( $p = 0.001$ ), not reaching PCR ( $p = 0.009$ ), low neutrophil count ( $< 1.5\text{G/L}$ ) ( $p = 0.007$ ), and high PLR ( $\geq 150$ ) ( $p = 0.044$ ) were all correlated to a higher risk of relapse in univariate analysis.

In multivariate analysis, high PLR was still an independent prognostic factor (HR = 1.91; 95%CI = 1.15-3.16;  $p = 0.012$ ) as well as low neutrophil count ( $<1.5\text{ G/L}$ ) (HR = 0.06; 95%CI = 0.03-0.12;  $p < 0.001$ ). Other independent prognostic factors for RFS were high tumor size (HR = 2.07; 95%CI = 1.26-3.39;  $p = 0.004$ ), TNBC subtype (HR = 4.11; 95%CI = 2.28-7.42;  $p < 0.001$ ) and PCR achievement (HR = 0.27; 95%CI = 0.12-0.56;  $p = 0,001$ ).

#### Prognostic factors for OS (Table 4)

At the end of follow-up, 51 patients (18.2%) had died, including 40 BC-related deaths. Other deaths were due to a second cancer for 6 patients, chemotherapy related toxicity (cardiac failure) for one patient, intercurrent disease for one patient and unknown for 3 patients.

In univariate analysis, the following factors were correlated to a poor survival: higher tumor size ( $p = 0.006$ ), inflammatory BC ( $p = 0.014$ ), hormone receptor negative BC ( $p = 0.001$ ), TNBC ( $p < 0.001$ ), not reaching PCR ( $p = 0.041$ ) and platelet count  $\geq 264\text{ G/L}$  ( $p = 0.049$ ).

In multivariate analysis, high PLR and low neutrophil count ( $< 1.5\text{ G/L}$ ) were associated to shorter OS (HR = 1.83; 95%CI = 1.03-3.24;  $p = 0.039$  and HR = 0.12; 95%CI = 0.06-0.24;  $p < 0.001$ , respectively). Other independent prognostic factors for OS were high tumor size (HR = 2.43; 95%CI = 1.37-4.30;  $p = 0.002$ ), TNBC subtype (HR = 6.59; 95%CI = 3.34-13.01;  $p < 0.001$ ) and PCR achievement (HR = 0.29; 95%CI = 0.13-0.66;  $p = 0.003$ ).

#### Sub group analyses

Platelet count, neutrophil count, lymphocyte count, PLR or NLR were not predictive factors for PCR in any of the molecular subtypes. Low white blood cell count ( $< 6.75\text{ G/L}$ ) was an independent predictive factor for PCR in patients with TNBC (OR = 0.29; 95%CI = 0.14-0.61;  $p$



< 0.01); but not for other molecular subtypes. Data for survival were not mature enough to highlight prognostic factors according to the molecular subtype.

#### Predictive factors for febrile neutropenia (Table 5)

Thirty-eight patients (13.6%) patients developed FN during NACT. Post-menopausal status ( $p = 0.005$ ), negative hormone receptor ( $p = 0.003$ ), low platelet count ( $< 264$  G/L) ( $p = 0.015$ ), low white blood cell count ( $< 6.75$  G/L) ( $p = 0.002$ ) and low NLR ( $p = 0.001$ ) were predictive for FN in univariate analysis. Molecular subgroup was predictive for since 34.9% of positive hormone receptor-Her2 negative patients developed FN, 32.6% of negative hormone receptor-Her2 negative patients developed FN, 27.9% of negative hormone receptor-Her2 positive patients developed FN and only 4.7% of patients with positive hormone receptor and positive Her2 status developed FN ( $p = 0.007$ ).

In multivariate analysis, low NLR was independently predictive for FN (OR = 0.28; 95%CI = 0.13-0.58;  $p = 0.001$ ) as well as low platelet count ( $< 264$  G/L) and low white blood cell count ( $< 2.75$  G/L) (OR = 0.40; 95%CI = 0.21-0.75;  $p = 0.004$  and OR = 0.35; 95%CI = 0.17-0.72;  $p = 0.004$ , respectively). Clinical tumor size was also a predictive factor for FN (OR = 0.43; 95%CI = 0.20-0.91;  $p = 0.028$ ). Patient with positive hormone receptor and positive Her2 status developed less FN than patients with positive hormone receptor and negative Her2 status (OR = 0.21; 95%CI = 0.005-0.93;  $p = 0.039$ ). Other molecular subtypes were not independently associated with FN.

We also calculated a cut-off for NLR to be predictive for FN, this cut-off point was set at 4.125, meaning that patients with an initial NLR higher than 4.125 had fewer risk of FN (AUC = 0.52;  $p = 0.308$ ). Seventeen patients (6.1%) had NLR  $\geq 4.125$  and the risk of FN for this group was 1.4%. Two hundred and sixty-three patients (93.1%) had NLR lower than 4.125 and the risk of FN for this group was 13.9%.

## DISCUSSION

We report here the correlations between IBM and clinical endpoints in a homogeneous population of 280 BC patients treated with NACT in a single institution. We showed that PLR is an independent prognostic factor for RFS and OS and that NLR is an independent predictive

factor for FN. None of the IBM were predictive for PCR in our overall population. When focusing on specific molecular subtypes, white blood cell count was an independent predictive factor for PCR in TNBC. In addition, as previously reported (3,4) we found a highly significant correlation between PCR and survival, PCR being prognostic both for RFS and OS in univariate and multivariate analyses in our study.

This is the second largest cohort of patients published regarding IBM as predictive factor (after Graziano *et al*'s study (29)) and the largest population with reported multivariate results regarding IBM as prognostic factor in patients with localized BC homogeneously receiving NACT. Our population is representative for patients receiving NACT since most of our patients were affected by cT2 stage (or higher), node positive BC. We chose to include the four molecular subtypes in order to have a comprehensive evaluation of the correlations between IBM and NACT in BC patients.

Most of the studies evaluating IBM as prognostic factor studied Asian-based populations (9,20,22,24,27,28,30–41) where use of anti-cancer drugs, particularly trastuzumab is inconsistently reported, inducing heterogeneity in survival expectations. This demographic variable could be associated with specific molecular and pharmacological features that can induce differences in toxicity and efficacy profiles. We report here a large population of western BC patients receiving sequential anthracycline and taxane-based chemotherapy, with access to anti-Her2 therapies.

Another strength of our series is the long clinical follow-up, with a median duration of more than 6 years, a substantially longer follow-up than most of the similar studies, allowing a relevant and mature evaluation of survival data.

Finally, we are the first ones to evaluate the relation between IBM and toxicity in a population of EBC patients receiving NACT and we found that low NLR was an independent predictive factor for FN.

One limitation comes from the monocentric, retrospective nature of our studied population. However, the clinicopathological characteristics of our population and our results are consistent with previously published studies evaluating IBM. In a closely-related population of BC patients receiving adjuvant treatment, Ramos Esquivel *et al* (42), Takeuchi *et al* (24) and Cho *et al* (36) also showed that PLR was a prognostic factor for disease-free survival (DFS) and

OS in univariate and multivariate analyses. In a population of patients with metastatic TNBC, Vernieri *et al* (43), found that PLR was statistically significantly associated to progression-free survival. Only one study (written by Losada *et al* (44)) evaluating PLR as prognostic factor in patients receiving NACT failed to show evidence of a relation between PLR and DFS. Therefore, their population was different from ours since they included only elderly patients ( $\geq 65$  years old).

Results on NLR and survival are more controverted. In population receiving NACT, two studies (Suppan *et al* (45), and Marin Hernandez *et al* (46)) found, similarly to us, that NLR was not prognostic for DFS and / or OS, whereas two other studies (Chen *et al* (20), and Koh *et al* (31)) found that NLR was associated with survival. These conflicting results could be due to a difference in the studied population since both Chen *et al* and Koh *et al* had fewer or none TNBC patients in their studied population, while Suppan *et al*, Marin Hernandez *et al* and our study included over 20% of TNBC patients. NLR prognostic value appears more clearly validated in the population of patients receiving adjuvant chemotherapy, since many studies have demonstrated a significant correlation in this setting (22,23,28,32,34,37,39,41,47–50).

In our population, we found no significant correlation between NLR nor PLR with PCR, concordantly with previous reports (26,29,30,44,45), evaluating a similar population of BC patients receiving NACT. Only one study (Chae *et al* (27)) found that NLR was predictive for PCR, however, they included only Chinese patients with TNBC, differing strikingly from our population. Cuello Lopez *et al* (51) reported, in univariate analysis, that patients with low PLR had higher PCR rates, but no multivariate data were available in this publication.

As previously said, we are the first study, to our knowledge, to analyze data on the correlations between IBM and chemotherapy-related toxicity in BC patients receiving NACT. Evaluation of IBM, accessible through a simple blood analysis, could appear as an interesting, inexpensive tool to individualize one's hematological risk under NACT. Considering NLR as a predictive factor for FN could help to decide, for example, which patients should benefit from granulocyte colony stimulating factors in intermediate risk situations (52). The only data available on NLR and toxicity in this situation were published by Yamanouchi *et al* (53) and they found no significant correlation. However, the population was limited (67 metastatic BC patients), possibly explaining the lack of statistical significance. Two authors evaluated lymphopenia as a predictive factor for toxicity. Ray Coquard *et al* conducted two studies

(54,55) showing that lymphocyte count at day one of chemotherapy  $< 0.7$  G/L was an independent prognostic factor for early death after chemotherapy and for FN, in large cohort of patients (including BC patients). Choi *et al* (56), in contrary couldn't establish a relation between day one lymphopenia and FN in a cohort of patients (including 13% of BC patients) receiving their first course of chemotherapy.

Another limitation of our work is our inability to robustly evaluate if IBM could be predictive for non-hematological toxicities, due to a small number of these events in our retrospective series. Dedicated studies on cardiac, neurological, or hepatic toxicities remains necessary to draw conclusion regarding possible associations between IBM and these toxicities.

NLR has also been studied in other cancers, and more specifically in patients receiving NACT. Chen *et al* (57) found a relation between NLR and DFS / OS in univariate but not in multivariate analysis in 91 patients receiving NACT for stomach cancer. Shen *et al* (58) did not find any correlation between NLR and survival in 202 patients receiving neoadjuvant chemo-radiotherapy for locally advanced rectal cancer. Buisan *et al* (59) found that NLR was prognostic for survival in 50 patients with squamous-cells features bladder cancer receiving NACT. Li *et al* (13) published a large meta-analysis on 6243 patients affected by different kind of cancer (including 1 507 BC) receiving NACT. He showed that high NLR was associated with a lower PCR rate, low NLR was associated with better OS, cancer specific survival, DFS and recurrent free survival. Whether the discrepancies between our work and this meta-analysis are linked to statistical power or heterogeneity of the prognostic value of NLR between tumor types need to be further evaluated.

In conclusion, IBM are an easy and efficient tool to evaluate patient's prognostic and the risk of FN. Additional studies evaluating larger populations, as well dedicated prospective studies, are needed in order to evaluate if IBM could also be reliably predictive for PCR.

Table 1: Patients characteristics

Characteristics	No (%)
Age (median)	50.3 (25.3-76.6)
Menopausal status	
Yes	103 (36.8)
No	177 (63.2)
T stage (before NACT)	
T0	2 (0.7)
T1	22 (7.9)
T2	165 (58.9)
T3	47 (16.8)
T4	43 (15.4)
Missing	1 (0.3)
Node status (before NACT)	
N-	129 (46.1)
N+	145 (51.8)
Missing	6 (2.1)
Inflammatory BC	
Yes	39 (14.2)
No	241 (85.8)
Histology	
Ductal	235 (84)
Lobular	27 (9.6)
Other	18 (6.4)
Histological grade	
1	5 (1.8)
2	123 (43.9)
3	146 (52.2)
Missing	6 (2.1)
Differentiation (N=215)	
1	1 (0.5)
2	21 (9.8)
3	193 (89.7)

Characteristics	No (%)
Nucleus (N=216)	
1	3 (1.4)
2	77 (35.6)
3	136 (63)
Mitosis (N=216)	
1	70 (32.4)
2	70 (32.4)
3	76 (35.2)
Her2 status	
Positive	81 (28.9)
Negative	199 (71.1)
HR status	
Positive	168 (60)
Negative	112 (40)
Molecular subtype	
HR+/Her2-	127 (45.4)
HR+/Her2+	41 (14.6)
HR-/Her2+	40 (14.3)
HR-/Her2-	72 (25.7)
Baseline biology : median (range)	
Hemoglobin (g/dl)	13.6 (8.0-15.4)
Platelets (G/L)	264 (124-452)
White blood cell count (G/L)	6.8 (1.5-30)
Lymphocyte count (G/L)	1.9 (0.6-26)
PNN (G/L)	3.9 (1.4-11.6)
NLR	2.0 (0.1-17.3)
PLR	132.3 (6.9-514.9)

NACT: neo adjuvant chemotherapy, BC: breast cancer, HR: hormone receptor, PNN: neutrophils, NLR: neutrophil to lymphocyte ratio, PLR: neutrophil to lymphocyte ratio

Table 2: Univariate and multivariate logistic regression of predictive factors for pathological complete response (PCR)

PCR Variable	Univariate				Multivariate	
	No	Yes	Total	p	Odd Ratio (95%CI)	p
Age (year)				0.278		
• < 50.25	99 (48.1%)	41 (55.4%)	140 (50%)			
• ≥ 50.25	107 (51.9%)	33 (44.6%)	140 (50%)			
cT				0.895		
• T 0/2	140 (68.0%)	49 (67.1%)	189 (67.7%)			
• T 3/4	66 (32.0%)	24 (32.9%)	90 (32.3%)			
cN				0.093		
• Negative	88 (44.0%)	41 (55.4%)	129 (47.1%)		1	
• Positive	112 (56.0%)	33 (44.6%)	145 (52.9%)		0.43 (0.23-0.82)	0.010
Inflammatory BC				0.967		
• No	174 (85.7%)	61 (85.9%)	235 (85.8%)			
• Yes	29 (14.3%)	10 (14.1%)	39 (14.2%)			
Histological grade				0.001		
• 1					1	
• 2	106 (52.5%)	22 (30.6%)	128 (46.7%)		0.13 (0.07-0.27)	<0.001
• 3	96 (96 (47.5%))	50 (69.4%)	146 (53.3)		0.28 (0.12-0.63)	0.002
Histologic type				0.233		
• Ductal	168 (81.5%)	67 (90.5%)	235 (83.9%)			
• Lobular	23 (11.2%)	4 (5.4%)	27 (9.7%)			
• Others	15 (7.3)	3 (4.1%)	18 (6.4%)			
Hormone receptor				<0.001		
• Negative	65 (31.6%)	47 (63.5%)	112 (40.0%)			
• Positive	141 (68.4%)	27 (36.5%)	168 (60.0%)			
Molecular subtype				<0.001		
• HR+ Her2 -	116 (56.3%)	11 (14.9%)	127 (45.4%)		1	
• HR+ Her2 +	25 (12.1%)	16 (21.6%)	41 (14.6%)		7.98 (3.13-20.34)	<0.001
• HR - Her2 +	18 (8.8%)	22 (29.7%)	40 (14.3%)		11.94 (4.76-29.91)	<0.001
• HR - Her2 -	47 (22.8%)	25 (33.8%)	72 (25.7%)		4.65 (1.98-10.89)	<0.001
Platelet count				0.068		
• < 264 G/L	97 (47.1%)	44 (59.5%)	141 (50.4%)			
• ≥ 264 G/L	109 (52.9%)	30 (40.5%)	139 (49.6%)			
White blood cell count				0.058		
• < 6.75 G/L	96 (46.6%)	44 (59.5%)	140 (50.0%)			
• ≥ 6.75 G/L	110 (53.4%)	30 (40.5%)	140 (50.0%)			
Neutrophil count				1.000		
• < 1.5 G/L	1 (0.5%)	0 (0.0%)	1 (0.4%)			
• ≥ 1.5 G/L	205 (99.5%)	74 (100.0%)	279 (99.6%)			
Lymphocyte count				0.685		
• < 1 G/L	7 (3.4%)	1 (1.4%)	8 (2.9%)			
• ≥ 1 G/L	199 (96.6%)	73 (98.6%)	272 (97.1%)			
NLR				0.550		
• < 2	103 (50.0%)	34 (45.9%)	137 (48.9%)			
• ≥ 2	103 (50.0%)	40 (54.1%)	143 (51.1%)			
PLR				0.617		
• < 150	132 (64.1%)	45 (60.8%)	177 (63.2%)			
• ≥ 150	74 (35.9%)	29 (39.2%)	103 (36.8%)			

BC: breast cancer, cT: clinical tumor size, cN: clinical node involvement, HR: hormone receptor, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio

Table 3: Univariate and multivariate logistic regression of prognostic factors for recurrence free survival (RFS)

RFS	Univariate		Multivariate		
	Variable	Hazard Ratio (95%CI)	p	Hazard Ratio (95%CI)	p
Age (year)					
• < 50.25	1				
• ≥ 50.25	1.50 (0.91-2.46)	0.111			
cT					
• T 0/2	1		1		
• T 3/4	2.01 (1.23-3.26)	0.005	2.07 (1.26-3.39)	0.004	
cN					
• Negative	1				
• Positive	1.61 (0.97-2.69)	0.066			
Inflammatory BC					
• No	1				
• Yes	2.34 (1.33-4.12)	0.003			
Histological grade					
• 1/2	1		1		
• 3	1.12 (0.68-1.84)	0.657	0.84 (0.47-1.51)	0.65	
Histologic type					
• Ductal	1				
• Lobular	0.93 (0.40-2.16)	0.866			
• Others	1.84 (0.84-4.06)	0.129			
HR					
• Negative	1				
• Positive	0.48 (0.29-0.78)	0.003			
Molecular subtype					
• HR+ Her2 -	1		1		
• HR+ Her2 +	1.135 (0.505-2.551)	0.759	1.55 (0.73-3.33)	0.253	
• HR - Her2 +	1.378 (0.634-2.993)	0.418	1.89 (0.86-4.14)	0.111	
• HR - Her2 -	2.669 (1.511-4.714)	0.001	4.11 (2.28-7.42)	<0.001	
PCR					
• No	1		1		
• Yes	0.37 (0.18-0.78)	0.009	0.27 (0.12-0.56)	0.001	
Platelet count					
• < 264 G/L	1				
• ≥ 264 G/L	1.73 (1.05-2.84)	0.031			
White blood cell count					
• < 6.75 G/L	1				
• ≥ 6.75 G/L	1.14 (0.70-1.86)	0.593			
Neutrophil count					
• < 1.5 G/L	1		1		
• ≥ 1.5 G/L	0.06 (0.01-0.48)	0.007	0.06 (0.03-0.12)	< 0.001	
Lymphocyte count					
• < 1 G/L	1				
• ≥ 1 G/L	0.89 (0.22-3.64)	0.871			
NLR					
• < 2	1				
• ≥ 2	1.02 (0.63-1.66)	0.930			
PLR					
• < 150	1		1		
• ≥ 150	1.65 (1.01-2.69)	0.044	1.91 (1.15-3.16)	0.012	

cT: clinical tumor size, cN: clinical node involvement, BC: breast cancer, HR: hormone receptor, PCR: pathological complete response, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio

Table 4: Univariate and multivariate logistic regression of prognostic factors for overall survival (OS)

OS	Univariate		Multivariate	
	Hazard Ratio (95%CI)	p	Hazard Ratio (IC95%CI)	p
Age (year)				
• < 50.25	1			
• ≥ 50.25	1.60 (0.91-2.83)	0.103		
cT				
• T 0/2	1		1	
• T 3/4	2.15 (1.24-3.73)	0.006	2.43 (1.37-4.30)	0.002
cN				
• Negative	1			
• Positive	1.42 (0.80-2.51)	0.232		
Inflammatory BC				
• No	1			
• Yes	2.21 (1.17-4.16)	0.014		
Histological grade				
• 1/2	1			
• 3	1.00 (0.57-1.76)	0.993		
Histologic type				
• Ductal	1			
• Lobular	0.76 (0.27-2.12)	0.604		
• Others	1.20 (0.43-3.33)	0.732		
HR				
• Negative	1			
• Positive	0.37 (0.21-0.65)	0.001		
Molecular subtype				
• HR+ Her2 -	1		1	
• HR+ Her2 +	1.33 (0.15-3.47)	0.555	1.77 (0.72-4.34)	0.211
• HR – Her2 +	1.15 (0.41-3.20)	0.785	1.44 (0.50-4.13)	0.501
• HR – Her2 -	4.15 (2.16-7.96)	<0.001	6.59 (3.34-13.01)	<0.001
PCR				
• No	1		1	
• Yes	0.43 (0.20-0.97)	0.041	0.29 (0.13-0.66)	0.003
Platelet count				
• < 264 G/L	1			
• ≥ 264 G/L	1.76 (1.00-3.09)	0.049		
White blood cell count				
• < 6.75 G/L	1			
• ≥ 6.75 G/L	1.39 (0.80-2.41)	0.248		
Neutrophil count				
• < 1.5 G/L	1		1	
• ≥ 1.5 G/L	0.16 (0.02-1.17)	0.071	0.12 (0.06-0.24)	<0.001
Lymphocyte count				
• < 1 G/L	1			
• ≥ 1 G/L	0.70 (0.71-2.89)	0.624		
NLR				
• < 2	1			
• ≥ 2	0.96 (0.55-1.66)	0.890		
PLR				
• < 150	1		1	
• ≥ 150	1.49 (0.85-2.60)	0.160	1.83 (1.03-3.24)	0.039

cT: clinical tumor size, cN: clinical node involvement, BC: breast cancer, HR: hormone receptor, PCR: pathological complete response, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio



Table 5 : multivariate logistic regression of predictive factors for febrile neutropenia

Febrile Neutropenia	Univariate				Multivariate	
	No	Yes	Total	p	Odd Ratio (95%CI)	p
Age (year)				0.068		
• < 50.25	124 (52.3%)	16 (37.2%)	140 (50.0%)			
• ≥ 50.25	113 (47.7%)	27 (62.8%)	140 (50.0%)			
cT				0.170		
• T 0/2	156 (66.1%)	33 (76.7%)	189 (67.7%)		1	
• T 3/4	80 (33.9%)	10 (23.3%)	90 (32.3%)		0.43 (0.20-0.91)	0.028
cN				0.559		
• Negative	107 (46.3%)	22 (21.2%)	129 (47.1%)			
• Positive	124 (53.7%)	21 (48.8%)	145 (52.9%)			
Inflammatory BC				0.936		
• No	200 (85.8%)	35 (85.4%)	235 (85.8%)			
• Yes	33 (14.2%)	6 (14.6%)	39 (14.2%)			
Histological grade				0.228		
• 1						
• 2	112 (48.3%)	16 (38.1%)	128 (46.7%)			
• 3	120 (51.7%)	26 (61.9%)	146 (53.3%)			
Histologic type				1.000		
• Ductal	198 (82.5%)	37 (86.0%)	235 (83.9%)			
• Lobular	23 (9.6%)	4 (9.3%)	27 (9.6%)			
• Others	16 (7.9%)	2 (4.7%)	18 (6.5%)			
HR				0.003		
• Negative	86 (36.3%)	26 (60.5%)	112 (40.0%)			
• Positive	151 (63.7%)	17 (39.5%)	168 (60.0%)			
Molecular subtype				0.007		
• RH+ Her2 -	112 (47.3%)	15 (34.5%)	127 (45.5%)		1	
• RH+ Her2 +	39 (16.5%)	2 (4.8%)	41 (14.6%)		0.21 (0.05-0.93)	0.039
• RH - Her2 +	28 (11.7%)	12 (27.9%)	40 (14.3%)		2.18 (0.93-5.11)	0.072
• RH - Her2 -	58 (24.5%)	14 (32.8%)	72 (25.6%)		1.09 (0.51-2.34)	0.826
Platelet count				0.014		
• < 264 G/L	112 (47.3%)	29 (67.4%)	141 (50.4%)		1	
• ≥ 264 G/L	125 (52.7%)	14 (32.6%)	139 (49.6%)		0.40 (0.21-0.75)	0.004
White blood cell count				0.002		
• < 6.75 G/L	109 (46.0%)	31 (72.1%)	140 (50.0%)		1	
• ≥ 6.75 G/L	128 (54.0%)	12 (27.9%)	140 (50.0%)		0.35 (0.17-0.72)	0.004
Neutrophil count				0.154		
• < 1.5 G/L	0 (0.0%)	1 (2.3%)	1 (0.4%)			
• ≥ 1.5 G/L	237 (100.0%)	42 (97.7%)	279 (99.6%)			
Lymphocyte count				1.000		
• < 1 G/L	7 (3.0%)	1 (2.3%)	8 (2.9%)			
• ≥ 1 G/L	230 (97.0%)	42 (97.7%)	272 (97.1%)			
NLR				0.001		
• < 2	106 (44.7%)	31 (72.1%)	137 (48.9%)		1	
• ≥ 2	131 (55.3%)	12 (27.9%)	143 (51.1%)		0.28 (0.13-0.58)	0.001
PLR				0.532		
• < 150	148 (62.4%)	29 (67.4%)	177 (63.2%)			
• ≥ 150	89 (37.6%)	14 (32.6%)	103 (36.8%)			

cT: clinical tumor size, cN: clinical node involvement, BC: breast cancer, HR: hormone receptor, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio

## BIBLIOGRAPHY

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018 Nov;68(6):394–424.
2. Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. *Ann Surg Oncol.* 2015 May;22(5):1441–6.
3. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet Lond Engl.* 2014 Jul 12;384(9938):164–72.
4. Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Glück S, Crane R, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). *Contemp Clin Trials.* 2018;71:194–8.
5. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. *FEBS Open Bio.* 2015;5:502–7.
6. Faria SS, Fernandes PC, Silva MJB, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedicallscience.* 2016;10:702.
7. Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. *OncoTargets Ther.* 2016;9:5567–75.
8. Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res BCR.* 2017 05;19(1):2.
9. Liu X, Qu J-K, Zhang J, Yan Y, Zhao X-X, Wang J-Z, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. *Medicine (Baltimore).* 2017 Nov;96(45):e8101.
10. Ou Q, Cheng J, Zhang L, Wang H, Wang W, Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? *Tumour Biol J Int Soc Oncodevelopmental Biol Med.* 2017 Jun;39(6):1010428317706214.
11. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. *Medicine (Baltimore).* 2018 Dec;97(49):e13340.
12. Xue LB, Liu YH, Zhang B, Yang YF, Yang D, Zhang LW, et al. Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. *Medicine (Baltimore).* 2019 Jan;98(1):e13842.

13. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. *J Cancer*. 2018;9(5):861–71.
14. Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse J-P, Romieu G, et al. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. *Breast Cancer Res Treat*. 2012 Jul;134(2):709–17.
15. Chiba A, Raman R, Thomas A, Lamy P-J, Viala M, Pouderoux S, et al. Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. *Clin Breast Cancer*. 2018;18(2):144–9.
16. Viala M, Chiba A, Thezenas S, Delmond L, Lamy P-J, Mott SL, et al. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. *BMC Cancer*. 2018 Jul 30;18(1):770.
17. Fan Y-S, Casas CE, Peng J, Watkins M, Fan L, Chapman J, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. *Breast Cancer Res Treat*. 2016 Feb;155(3):457–62.
18. Hennequin C, Barillot I, Azria D, Belkacémi Y, Bollet M, Chauvet B, et al. [Radiotherapy of breast cancer]. *Cancer Radiother J Soc Francaise Radiother Oncol*. 2016 Sep;20 Suppl:S139-146.
19. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2010 May 1;21(suppl\_5):v252–6.
20. Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. *BMC Cancer*. 2016 19;16:320.
21. Cihan YB, Arslan A, Cetindag MF, Mutlu H. Lack of Prognostic Value of Blood Parameters in Patients Receiving Adjuvant Radiotherapy for Breast Cancer. *Asian Pac J Cancer Prev*. 2014 May 30;15(10):4225–31.
22. Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. *PLoS ONE* [Internet]. 2015 Nov 18 [cited 2019 Apr 28];10(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666347/>
23. Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. *ESMO Open* [Internet]. 2016 Mar 7 [cited 2019 Apr 28];1(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070254/>

24. Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. *PLoS ONE* [Internet]. 2017 May 10 [cited 2019 Apr 28];12(5). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425200/>
25. Ferroni P, Roselli M, Buonomo OC, Spila A, Portarena I, Laudisi A, et al. Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. *Anticancer Res*. 2018 Jan 8;38(8):4705–12.
26. Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. *Asian Pac J Cancer Prev*. 2014 Oct 11;15(18):7737–40.
27. Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, et al. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. *Curr Oncol*. 2018 Apr;25(2):e113–9.
28. Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, et al. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. *Tumor Biol*. 2016 Mar;37(3):4135–42.
29. Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. *The Breast*. 2019 Apr;44:33–8.
30. Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J, et al. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. *OncoTargets Ther*. 2018;11:1423–32.
31. Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. *Tumor Biol*. 2014 Oct;35(10):9823–30.
32. Noh H, Eomm M, Han A. Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. *J Breast Cancer*. 2013 Mar;16(1):55–9.
33. Nakano K, Hosoda M, Yamamoto M, Yamashita H. Prognostic Significance of Pre-treatment Neutrophil: Lymphocyte Ratio in Japanese Patients with Breast Cancer. *Anticancer Res*. 2014 Jan 7;34(7):3819–24.
34. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. *OncoTargets Ther*. 2014 Sep 26;7:1743–52.

35. ZHANG P, ZONG Y, LIU M, TAI Y, CAO Y, HU C. Prediction of outcome in breast cancer patients using test parameters from complete blood count. *Mol Clin Oncol*. 2016 Jun;4(6):918–24.
36. Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. Lafrenie RM, editor. *PLOS ONE*. 2018 Jul 26;13(7):e0200936.
37. Geng S-K, Fu S-M, Fu Y-P, Zhang H-W. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection. *Medicine (Baltimore)* [Internet]. 2018 Aug 21 [cited 2019 Apr 28];97(35). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392639/>
38. Fujimoto Y, Ozawa H, Higuchi T, Miyagawa Y, Bun A, Imamura M, et al. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. *Mol Clin Oncol*. 2019 Feb;10(2):275–84.
39. Qiu X, Song Y, Cui Y, Liu Y. Increased neutrophil–lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients. *IUBMB Life*. 2018 Jun 1;70(6):529–35.
40. Lee SK, Choi M-Y, Bae SY, Lee JH, Lee H-C, Kil WH, et al. Immediate Postoperative Inflammation Is an Important Prognostic Factor in Breast Cancer. *Oncology*. 2015 Feb 25;88(6):337–44.
41. Kim YY, Park HK, Lee KH, Kim KI, Chun YS. Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer. *J Breast Cancer*. 2016 Jun;19(2):163–8.
42. Ramos-Esquivel A, Rodriguez-Porras L, Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. *Breast Dis*. 2017 Jan 1;37(1):1–6.
43. Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep* [Internet]. 2018 Jun 7 [cited 2019 May 14];8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992181/>
44. Losada B, Guerra JA, Malón D, Jara C, Rodriguez L, Del Barco S. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. *Clin Transl Oncol* [Internet]. 2018 Nov 30 [cited 2019 Apr 28]; Available from: <http://link.springer.com/10.1007/s12094-018-1999-9>
45. Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, et al. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. *BMC Cancer* [Internet]. 2015 Dec 29

[cited 2019 Apr 11];15. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696229/>

46. Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, Galindo Fernández PJ, Ruiz Merino G, Alonso Romero JL, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. *Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex*. 2018 Apr;20(4):476–83.
47. Forget P, Bentin C, Machiels J-P, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. *Br J Anaesth*. 2014 Jul;113:i82–7.
48. Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? *Int J Clin Oncol*. 2015 Feb;20(1):70–81.
49. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. *BMC Cancer [Internet]*. 2015 Mar 28 [cited 2019 Apr 28];15. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428113/>
50. Liu C, Huang Z, Wang Q, Sun B, Ding L, Meng X, et al. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. *OncoTargets Ther*. 2016 Jul 27;9:4653–60.
51. Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, Vásquez-Trespalcacios E. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. *PLoS ONE [Internet]*. 2018 Nov 14 [cited 2019 Apr 11];13(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235359/>
52. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur J Cancer Oxf Engl 1990*. 2011 Jan;47(1):8–32.
53. Yamanouchi K, Kuba S, Sakimura C, Morita M, Kanetaka K, Kobayashi K, et al. The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer. *Anticancer Res*. 2017 Jan 12;37(12):6947–51.
54. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. *Br J Cancer*. 2001 Sep;85(6):816–22.
55. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. *Br J Cancer*. 2003 Jan 27;88(2):181–6.

56. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. *Am J Hematol*. 2003;73(4):263–6.
57. Chen L, Zuo Y, Zhu L, Zhang Y, Li S, Ma F, et al. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. *OncoTargets Ther*. 2017;10:2569–80.
58. Shen J, Zhu Y, Wu W, Zhang L, Ju H, Fan Y, et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. *Med Sci Monit Int Med J Exp Clin Res*. 2017 Jan 19;23:315–24.
59. Buisan O, Orsola A, Oliveira M, Martinez R, Etxaniz O, Areal J, et al. Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy. *Clin Genitourin Cancer*. 2017;15(4):e697–706.

## **Article 2**

**Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review**

**Evaluation du ratio neutrophiles sur lymphocytes comme facteur pronostique et prédictif dans le cancer du sein : revue de la littérature.**

Iléana CORBEAU, William JACOT, Séverine GUIU



## ABSTRACT

Inflammatory blood markers (IBM), such as neutrophil to lymphocyte ratio (NLR), have emerged as potential prognostic factors in various cancers, including breast cancer (BC), potentially allowing an easy, minimally invasive, evaluation of a given cancer's prognosis and treatment outcome. We report here a systematic overview of published data evaluating NLR as prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC. A total of 45 articles were identified. NLR was found to be an independent prognostic factor for survival in most of the adjuvant treatment studies. However, no significant correlation was found between survival and NLR for early BC patients receiving neo-adjuvant chemotherapy (NACT) and advanced BC patients. Most studies failed to find a significant correlation between NLR and PCR after NACT. Finally, some data showed that IBM could be predictive of chemotherapy-related toxicity.

Keywords: breast cancer, inflammatory blood markers, neutrophil to lymphocyte ratio, prognostic factor, predictive factor, pathological complete response, toxicity

## 1. INTRODUCTION

Breast cancer (BC) is a heterogeneous disease, its prognosis depending on the tumor stage (localized disease *versus* metastatic disease) and the molecular subtype. Today's management of BC includes multidisciplinary and multimodal treatments such as surgery, radiation therapy, chemotherapy (CT), endocrine therapy and / or targeted therapies (1,2). Some predictive and / or prognostic factors are well known (for example hormone receptor status, Her2 overexpression / amplification, histological grade or stage). However, there is a persistent need for more predictive and prognostic factors in order to adapt as precisely as possible each patients' treatment.

Over the past few years, inflammatory blood markers (IBM) have emerged as predictive and prognostic factors, and especially the neutrophil to lymphocyte ratio (NLR) defined as the ratio of absolute neutrophil count to absolute lymphocyte count. Lymphopenia and high NLR before CT initiation have been inconsistently reported to be associated with worse response to neoadjuvant chemotherapy (NACT) and to poor prognosis in different cancer types, including BC (3,4).

The role of inflammation on cancer is now well established (5) and has been described at the different stages of cancer development (initiation, promotion, invasion and metastasis). Activated inflammation cells serve as sources of Reactive Oxygen Species (ROS) and Reactive Nitrogen intermediate (RNI) that can induce DNA damage and genome instability therefore initiating cancer (6,7) or interfering with DNA repair systems (8). Inflammation enhances the production of growth factors and cytokines that can confer a stem-cell like phenotype upon tumor progenitors; it also involves the angiogenetic switch which favors tumor progression. Neutrophils in particular have more and more been studied and there is now evidences that neutrophils can promote tumor growth and play a role in metastasis development (9,10). Their ability to secrete proteases, and particularly matrix metalloproteases (MMP) helps them promoting tumor invasion. They are also involved in tumor progression through their capacity to activate signal transducer and activators of transcription 3 (STAT3) and through their capacity to promote neo-angiogenesis (11).

Tumor infiltrating lymphocytes (TILs) have been widely studied in recent years, especially in BC (12). It has been shown that TILs, and more particularly lymphocytes belonging to the

innate arm of the immune system, were likely to recognize and eliminate malignant cells. Therefore, they play a central role and low TILs could be predictive for fewer responses to NACT (13) and associated to poor prognosis (14,15).

Peripheral IBM could be helpful for predicting both patients' prognosis and the response to NACT in BC. Many studies have evaluated NLR, with conflicting results regarding its ability to be a predictive and / or a prognostic factor (11,16–21). Total white blood cell count, neutrophil count, lymphocyte count or other ratios such as platelet to lymphocyte ratio (PLR) have also been studied with the same conflicting results.

Here we systematically collected published data evaluating the predictive or prognostic role of NLR in BC patients. We will first summarize the published data on NLR and treatment efficacy regarding survival (disease free survival [DFS], breast cancer specific survival [BCSS] and overall survival [OS]) in patients with early BC (receiving NACT or adjuvant treatment) and in patients with advanced BC. We will also summarize data on the predictive value of NLR for pathological complete response (PCR).

The second part of our work will evaluate the correlation between CT-related toxicity and NLR and / or lymphopenia.

## 2. MATERIAL AND METHODS

### 2.1 Search strategy

A systematic search on PubMed database was performed, using search terms of “neutrophil to lymphocytes ratio” AND “breast cancer” or “lymphopenia” AND “breast cancer”. We also looked for papers corresponding to the search for “toxicity” AND “neutrophil to lymphocyte ratio” OR “lymphopenia” AND “breast cancer”. Literature reviewing was updated on February 2019. Citation lists from article of interest found on PubMed were screened in order to ensure exhaustivity of the papers included in our work.

## 2.2 Study Selection (Figure 1)

For the first part of our work focusing on treatment efficacy, all articles with only BC cohort, PCR and / or survival analysis as primary objectives were included. Papers mixing different situations (neoadjuvant, adjuvant and metastatic settings) were excluded. For the second part focusing on toxicity, all articles reporting data about BC, IBM and CT-related toxicity were included. We excluded papers that were in another language than English.




Figure 1 Flow chart of the study selection

## 2.3 Data extraction

The following information were extracted from each study: name of first author and year of publication, population of interest, description of endpoints based on BC molecular subtypes, number of patients enrolled, ethnicity, treatment received, chosen cut-off for NLR, primary objective, results on primary objectives (univariate analysis), results on subgroup analysis (if applicable), secondary objectives and their results, existence of a multivariate model on NLR results and if so, results on multivariate model and adjustment covariates. We distinguished three populations: patients receiving NACT, patients receiving adjuvant treatment, and

patients with advanced BC. For toxicity, we selected articles that studied CT-related toxicity according to lymphocyte count or NLR. Data on population of interest, treatment received and toxicity were reported.

In cases of selected articles reporting data on other IBM (such as lymphocyte count or PLR) as predictive and / or prognostic factors, the data were included in our tables.

## 2.4 Definitions

DFS was defined as the time between the diagnosis (or the date of surgery for patients receiving adjuvant CT) and the date of relapse (local recurrence or metastases to distant sites) and / or death from any cause, whichever comes first, for some papers. Some papers used recurrence free survival (RFS) as primary objective. RFS had the same definition than DFS, therefore we used the term of DFS for DFS or RFS in this work.

BCSS was calculated from the date of diagnosis until the date the patient succumbed to the disease or last follow up time. Some papers reported data on disease specific survival (DSS) which had the same definition than BCSS, therefore we used the term of BCSS for BCSS or for DSS in this work.

OS was defined, for all studies, as the time between the date of diagnosis (or the first day of surgery) and the date of death due to any reason (and / or the date of last follow up for some papers).

Finally, progression-free survival (PFS) was defined as the time from treatment initiation to the date of disease progression or death from any cause.

## 3. RESULTS

### 3.1 Efficacy

#### 3.1.1 In early BC

##### 3.1.1.1 Patients receiving NACT (Table 1)

Ten studies reported data on NLR as predictive or prognostic factor in patients receiving NACT (22–31). Out of those 10 studies, 8 included patients with all molecular subtypes (22–29), one included only patients with triple negative breast cancer (TNBC) subtype (31) and another studied only patients with hormone

receptor positive / HER2-negative BC (30). The NLR cut off for statistical analyses was between 1.7 and 3.33 and was obtained by performing receiver operating characteristic (ROC) curves analysis for each study. Number of patients enrolled in studies was between 78 and 373. Half of the studies reported data on Asian population (23,25,28,30,31). In 9 studies NACT protocols was reported and was based on anthracycline and / or taxane regimens (23–31).

### *3.1.1.1.1 Results on PCR*

#### *3.1.1.1.1.1 Studies including all molecular subtypes*

Seven studies had PCR rate according to NLR as primary objective (22–25,27–29). For all studies (except for two with no definition reported), PCR was defined as complete disappearance of invasive tumour both in the breast and in the lymph nodes (patients with residual ductal carcinoma *in situ* were also considered to have achieved PCR: ypT0/is pN0). Out of those 7 studies, only 3 (43%) reported a significant correlation between NLR and PCR in univariate analysis (23,25,28). Only one study, from Qian *et al*, reported data with multivariate analysis and found that NLR was not an independent prognostic factor for PCR ( $p = 0.254$ ) (28).

#### *3.1.1.1.1.2 Studies including only specific molecular subtypes*

Chae *et al* studied 87 cases of TNBC and showed a relation between NLR and PCR in univariate and multivariate model (odds ratio [OR] = 4.274; 95%CI 1.451-12.658;  $p = 0.008$ ) (31).

#### *3.1.1.1.1.3 Subgroup analyses*

Suppan *et al* (24) compared patients that received both anthracyclines and taxanes and patients that received anthracyclines or taxanes. They didn't show any correlation between NLR and PCR in any of the two groups. They also compared the different molecular subtypes and did not identify a specific subgroup for which there would be a correlation between NLR and PCR.

Graziano *et al* (27) showed that patients with NLR<sup>low</sup> / PLR<sup>low</sup> had higher PCR rates than patients with NLR<sup>high</sup> / PLR<sup>high</sup> (OR = 1.98; 95%CI 1.01-3.89;  $p = 0.044$ ).

### *3.1.1.1.2 Results on DFS*

#### *3.1.1.1.2.1 Studies including all molecular subtypes*

DFS was a primary objective in 6 studies (23–26,28,29). Out of them, only two (33%) reported that higher NLR was correlated to shorter DFS in univariate analysis (25,26). Three studies (50%) reported data on NLR and DFS with multivariate analyses (24–26): only one of them (33%), written by Chen *et al* (25), found that NLR was an independent prognostic factor (HR = 1.57; 95%CI 1.05-3.57;  $p < 0.05$ ).

#### *3.1.1.1.2.2 Studies including only specific molecular subtypes*

Koh *et al* (30), that were interested in patients with hormone receptor positive / Her2 negative BC, reported that NLR was an independent prognostic factor for DFS in this population (HR = 3.87; 95%CI 1.64-9.14;  $p = 0.002$ ).

#### *2.1.1.1.2.3 Sub group analyses*

Asano *et al* (23) showed that in their sub-group of 61 patients with TNBC, NLR was correlated to DFS in univariate analysis but was not an independent prognostic factor for DFS.

### *3.1.1.1.3 Results on OS and BCSS*

#### *3.1.1.1.3.1 Studies including all molecular subtypes*

Four studies had data on NLR and OS with univariate analysis (23,26,28,29). Out of them only one (25%), written by Marin-Hernandez *et al* (26), showed a significant association between NLR and OS in univariate analysis but NLR was not found to be an independent prognostic factor for OS ( $p = 0.543$ ).

Chen *et al* (25) reported data on BCSS and showed that NLR is an independent prognostic factor for BCSS (HR = 2.21; 95%CI 1.01-4.39;  $p < 0.05$ ) in their population of 215 stages II and III BC.

#### *3.1.1.1.3.2 Studies including only specific molecular subtypes*

Koh *et al* (30) studied NLR as prognostic factor for OS in 157 patients with hormone receptor positive / Her2 negative BC and found it was an independent prognostic factor (HR = 24.87; 95%CI 3.1-201.3;  $p = 0.003$ ).

#### *3.1.1.1.3.3 Sub group analyses*

Koh *et al* (30) also showed that correlation between NLR and OS was even stronger in patients with stage III BC compared to patients with stage II BC.

#### *3.1.1.1.4 Conclusion on NLR as prognosis and predictive factor in patients receiving NACT*

Six papers reported data with multivariate analyses on patients receiving NACT (24–26,28,30,31). One out of two analyses (50%) found a correlation between NLR and PCR (31), two out four analyses (50%) found a correlation between NLR and DFS (25,30), two out of four analyses (50%) found a correlation between NLR and OS (30,31) and finally the only analysis on NLR and BCSS found a significant correlation (25). These 9 analyses included a total of 1 558 patients. Precaution should be taken on conclusions since out of the 6 studies, two studied only one specific molecular subtype (TNBC or hormone receptor positive / Her2 negative patients). Table 2 summarizes the multivariate analyses and adjustment factors.



Table 1: Articles including data on NLR as predictive and prognostic factor in patients receiving NACT

First author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objective (univariate analysis)	Results on multivariate model
Erylimaz 2014	<b>78 patients including</b> all molecular subtypes	NS	NLR predictive for PCR	2.33	- NLR and PCR	
Asano 2016	<b>177 patients</b> including 116 non TNBC (65.5%) 61 TNBC (34.5%)	Anthracyclines + taxanes	NLR predictive and prognostic	3 (chosen before statistical analysis)	- NLR and DFS ( $p = 0.849$ ) - NLR and OS ( $p = 0.965$ ) PCR was achieved in 28.6% with high NLR vs 56.9 patients with low NLR ( $p < 0.001$ )	
Suppan 2015	<b>247 patients</b> including 150 ER+ (60.7%) 134 PR+ (54.3%) 49 Her2 positive (19.8%)	Anthracyclines +Taxanes (58.3%); Anthracyclines (38.2%); Taxanes (2.8%); other (6.1%)	NLR predictive and prognostic	comparison of median NLR	- NLR and DFS ( $p = 0.363$ ) - NLR and PCR (OR = 1.081; $p = 0.053$ )	- NLR and DFS (HR = 1.01; $p = 0.738$ )
Chen 2016	<b>215 patients</b> including 120 luminal A (55.8%) 52 luminal B (24.2%) 25 Her2 positive (11.6%) 18 TNBC (8.4%)	Anthracyclines + taxanes (74.9%); anthracyclines (19.1%); taxanes (6%)	NLR predictive and prognostic	2.1	NLR <sup>low</sup> group showed higher PCR rate vs NLR <sup>high</sup> group (24.5% vs 14.3%; $p < 0.05$ ) + NLR and DFS (H = 2.11; $p < 0.05$ ) + NLR and BCSS (HR = 2.45; $p < 0.05$ )	+ NLR and DFS (HR = 1.57; $p < 0.05$ ) + NLR and BCSS (HR = 2.21; $p < 0.05$ )
Marin-Hernandez 2017	<b>150 patients</b> including 32 luminal A (21.3%) 44 luminal B (29.4%) 35 Her2 positive (23.3%) 39 TNBC (26%)	Anthracyclines + taxanes for all patients (except for 3 that recieved everolimus in the context of a clinical trial)	blood parameters as prognostic	3.33	+ NLR and DFS (OR = 0.39; $p = 0.019$ ) + NLR and OS (OR = 0.38; $p = 0.030$ )	- NLR and DFS ( $p = 0.154$ ) - NLR and OS ( $p = 0.543$ )
Graziano 2019	<b>373 patients</b> including 132 luminal A (35.4%) 44 luminal B/Her2 neg (11.8%) 69 luminal B/Her2 pos (18.5%) 62 TNBC (16.6%) 66 Her2 positive (17.7%)	Anthracyclines + taxanes (56.8%); others received anthracyclines or taxanes as single agent or combination	NLR predictive of PCR	2.42	- NLR and PCR (OR = 1.53; $p = 0.125$ ) - PLR and PCR (OR = 1.59; $p = 0.084$ )	
Qian 2018	<b>180 patients for PCR</b> including 24 luminal A (13.3%) 60 luminal B (33.3%) 18 Her2 positive (10%) 40 TNBC (22.2%) 38 not available (21.2%) <b>131 patients for survival</b>	Taxane and/or anthracyline based chemotherapy Only 40% of Her2 positive cancer where treated with trastuzumab	NLR/PLR predictive and prognostic	2.44	+ NLR and PCR (20% vs 7.8%; $p = 0.030$ ) survival analysis on 131 patients: - NLR and DFS ( $p = 0.535$ ) or OS (data not available)	- NLR and PCR ( $p = 0.254$ )

Table 1 (continued)

First author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objective (univariate analysis)	Results on multivariate model
Losada 2018	<b>104 elderly patients</b> (>65y) including 23 luminal A (20.4%) 57 luminal B (50.4%) 8 Her2 positive (7.1%) 25 TNBC (22.1%)	Anthracycline, taxanes or both (no more data)	NLR survival and PCR	3.33	- NLR and DFS ( $p = 0.42$ ) or OS ( $p = 0.38$ ) - NLR and PCR ( $p = 0.43$ )	
Koh 2014	<b>157 patients</b> with ER/PR+ and Her2-negative BC	Anthracyclines + taxanes (75.2%); anthracyclines (24.8%)	NLR prognostic	2.25	+ NLR and DFS (HR = 4.01; $p = 0.001$ ) + NLR and OS (HR=24.64; $p = 0.003$ )	+ NLR and DFS (HR = 3.87; $p = 0.002$ ) + NLR and OS (HR = 24.87; $p = 0.003$ )
Chae 2018	<b>87 TNBC</b>	Anthracyclines + taxanes (71.3%), Anthracyclines (28.7%)	NLR predictive of PCR	1.7	low NLR had higher PCR rate (42.1% vs 18.4%; $p = 0.018$ )	+ NLR and PCR (OR = 4.27; $p = 0.008$ )

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease free survival, OS: overall survival, NACT: neo adjuvant chemotherapy, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer

Table 2: Multivariate models (results and adjustment factors) for patients treated with NACT

All molecular subtypes					
	PCR	DFS	OS	BCSS	Total
Number of multivariate models	1	3	1	1	6
Number of unique patients	180	612	150	215	1157
NLR significantly associated with n (%)	0 (0%)	1 (33%)	0 (0%)	1 (100%)	2 (33%)
Adjustment factors (%)					
Hormone receptors	100	67	NI	100	
T	NI	100	100	100	
N	NI	67	NI	100	
Age	NI	33	100	NI	
Histological Grade	NI	33	NI	100	
Molecular subtype	100	NI	NI	NI	
Ki67	100	NI	NI	NI	
CRP	NI	33	NI	100	
Operation method	NI	33	NI	100	
Lymphocyte count	100	33	100	NI	
Monocyte count	NI	33	100	NI	
Neutrophil count	NI	33	100	NI	
LMR	NI	33	100	NI	
NMR	NI	33	100	NI	
TNBC					
	PCR				Total
Number of multivariate models	1				1
Number of unique patients	87				87
NLR significantly associated with n (%)	1 (100%)				1 (100%)
Adjustment factors (%)					
Histological subtype	100				
Histological grade	100				
Ki67	100				
ER+ Her2 negative					
		DFS	OS		Total
Number of multivariate models		1	1		2
Number of unique patients		157	157		157
NLR significantly associated with n (%)		1 (100%)	1 (100%)		2 (100%)
Adjustment factors (%)					
PCR		100	100		
All studies					
	PCR	DFS	OS	BCSS	Total
Number of multivariate models	2	4	2	1	9
Number of unique patients	267	769	307	215	1558
NLR significantly associated with n (%)	1 (50%)	2 (50%)	1 (50%)	1 (100%)	5 (55.5%)

NACT: neo adjuvant chemotherapy, PCR: pathological complete response, DFS: disease free survival, OS: overall survival, BCSS: breast cancer specific survival, NLR: neutrophil to lymphocyte ratio, LMR: lymphocyte to monocyte ratio, NMR: neutrophil to monocyte ratio, NI: not indicated

#### 3.1.1.1.5 Results on other IBM

Out of these studies, 4 (26–29) were also interested in total lymphocyte count (2 studies) (26,28) or total neutrophil count before treatment (2 studies) (26,28) and other ratios such as lymphocyte to monocyte ratio (LMR) (2 studies) (26,29), neutrophil to monocyte ratio (NMR) (2 studies) (26,29) and PLR (2 studies) (27,29) as predictive and prognostic factors. Lymphocyte count was not correlated to DFS nor OS in Marin Hernandez *et al's* study (26) but was an independent predictive factor for PCR in multivariate analysis in Qian *et al's* study (OR = 4.37; 95%CI 1.43-13.39;  $p=0.01$ ) (28). Neutrophil count was not correlated to PCR in Qian *et al's* study (28), was not correlated to OS either in Marin Hernandez *et al's* study (26), but was an independent prognosis factor in multivariate analysis for DFS in Qian *et al's* study (28). PLR was not correlated to PCR in Graniano *et al's* study (27) nor to DFS or OS in Lasada *et al's* study (29) (univariate analysis). Marin Hernandez *et al* (26) found no correlation between NMR, LMR and survival (DFS and OS) in univariate and multivariate analysis. These results are consistent with Losada *et al* that found no correlation between LMR nor NMR and DFS or OS (29).

#### 3.1.1.2 Patients receiving adjuvant treatment (Table 3)

Twenty-three studies reported data on NLR as prognostic factor in patients with localized BC receiving adjuvant treatment (32–53). Out of those 23 studies, 18 (78%) included patients with all molecular subtypes (32–48), while 4 studied only TNBC (49–52), and one studied hormone receptor negative cancer (whatever the Her2 status) (53). The NLR cut off for statistical analyses, obtained by performing ROC curves analysis for most of the studies (78%), was set between 1.34 and 4. Number of patients enrolled in the individual studies varied from 90 to 1570 patients. Fifteen studies (65%) reported data on Asian population (32,35,36,38,39,42–44,46–49,51,53). Adjuvant CT regimens were reported in only 6 studies, consisting on anthracyclines and / or taxanes-based regimens (33,38,43,45,48,51).

Table 3: Articles including data on NLR as prognosis factor in patients receiving adjuvant treatment

Author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objective (univariate analysis)	Results on multivariate model
Noh 2013	<b>442 patients</b> including 177 luminal A (48.7%) 69 luminal B (19.0%) 36 Her2 positive (10.0%) 81 TNBC (22.3)	NS	NLR as prognostic factor for DSS	2.5	+ NLR and DSS 5 year survival: 88.6% vs 96.4% ; 10 year survival : 84.3% vs 92.2% ; p = 0.009	+ NLR and BCSS (HR = 4.08; p = 0.003)
Cihan 2014	350 patients including 194 ER+ (55.4%) 183 PR+ (52.3%) 110 Her2 positive (31.4)	CT (94.3%) (based on anthracyclines for 71.7%)	NLR as prognostic factor for DFS and OS	NLR : 3 P	- NLR and DFS (OR = 0.8; p = 0.410) - NLR and OS (OR = 0.7; p = 0.432)	
Forget 2014	<b>720 patients</b> including 601 ER+ (83.5%) 573 PR+ (79.6%) 67 Her2 positive (9.3%)	NS	NLR as prognostic factor for DFS and OS	3.3	+ NLR and DFS (HR = 2.20; p = 0.004) + NLR and OS (HR = 2.70; p = 0.020)	+ NLR and DFS (HR = 1.99; p = 0.010) + NLR and OS (HR = 2.35; p = 0.046)
Nakano 2014	<b>167 patients</b> including 130 ER+ (77.8%) 93 PR+ (55.7%) 24 Her2 positive (14.4%)	NS	NLR as prognostic factor for DFS and DSS	2.5 (according to previous studies)	+ NLR and DFS (HR = 2.5; p = 0.004) + NLR and BCSS (HR = 3.2; p = 0.007)	- NLR and DFS (HR = 2.0; p = 0.070) + NLR and BCSS (HR=2.7; p = 0.045)
Yao 2014	<b>608 patients</b> including 330 luminal A (57.9%) 59 luminal B (10.3%) 83 Her2 positive (14.6%) 98 TNBC (17.2%)	NS	NLR as prognostic factor for OS	2.57	- NLR and DFS (p = 0.084) + NLR and OS (p < 0.001)	+ NLR and OS (RR = 3.63; p = 0.002)
Dirican 2015	<b>1527 patients</b> including 1019 ER+ (66.4%) 994 PR+ (64.7%) 249 Her2+++ (16.2%)	adjuvant CT for 83.3% NACT for 9.6%	NLR as prognostic factor for DFS and OS	4	+ NLR and DFS (HR = 2.18; p < 0.001) + NLR and OS (HR = 2.82; p < 0.001)	+ NLR and DFS (HR = 1.46; p = 0.028) + NLR and OS (HR = 1.91; p = 0.001)
Hong 2016	<b>487 patients</b> including 62 luminal A (12.7%) 244 luminal B (50.1%) 59 Her2 positive (12.1%) 94 TNBC (19.3%) 28 NA (5.7%)	adjuvant CT for 73.5% (anthracyclines 30.7%; taxanes 15.6% ; anthracyclines + taxanes 36%; others 17.7%)	NLR as prognostic factor for DFS	1.93	+ NLR and DFS (HR = 2.20; p = 0.002) - NLR and 5y-OS (90.8% vs 91.7%; p = 0.707)	+ NLR and DFS (HR = 1.87; p = 0.011)
Jia 2015	<b>1570 patients</b> including 1001 luminal (63.8%) 344 Her2 positive (21.9%) 225 TNBC (14.3%)	adjuvant CT for 85.4%	NLR as prognostic factor for DFS and OS	2.0	+ NLR and DFS (HR = 1.44; p = 0.005) + NLR and OS (HR = 1.58; p = 0.020)	+ NLR and DFS (HR = 1.50; p = 0.004) + NLR and OS (HR = 1.63; p = 0.022)

Table 3 (continued)

Author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objective (univariate analysis)	Results on multivariate model
Orditura 2016	<b>300 patients</b> including 77 luminal A (25.7%) 124 luminal B Her2 - (41.3%) 51 luminal B Her2 + (17%) 21 Her2 enriched (7%) 27 basal like (9%)	NS	NLR as prognostic factor for DFS	1.97	+ NLR and DFS (HR = 0.45; $p = 0.034$ )	+ NLR and DFS (HR = 2.64; $p = 0.013$ )
Ramos-Esquivel 2017	<b>172 patients</b> including 104 ER+ or PR+ and Her2 - (60.5%) 18 ER+ or PR+ and Her2 + (10.5%) 16 ER- and PR- and Her2 + (9.3%) 34 ER- and PR- and Her2 - (19.6%)	Adjuvant CT (83.1%), NACT (22.1%)	NLR as prognostic factor for DFS and OS	3	+ NLR and DFS (HR = 4.20; $p < 0.001$ ) + NLR and OS (HR = 4.20; $p < 0.001$ )	- NLR and DFS (HR = 1.97; $p = 0.146$ ) - NLR and OS (HR = 1.81; $p = 0.192$ )
Zhang 2016	<b>162 patients</b> including 87 ER+ (53.7%) 77 PR+ (47.6%) 37 Her2 positive (22.8%)	NS	NLR as prognostic factor for DFS	1.81 (according to median value)	+ NLR and DFS (HR = 1.81; $p = 0.042$ ) - NLR and OS	- NLR and DFS (HR = 1.43; $p = 0.223$ )
Takeuchi 2017	<b>296 patients</b> including 253 ER+ (85%) 222 PR+ (75%) 247 Her2 positive (83%)	Adjuvant therapy according to St Gallen recommendations	NLR as prognostic factor for DFS	2.06	- NLR and DFS	
Cho 2018	<b>661 patients</b> including 448 luminal (67.8%) 96 Her2 positive (14.5%) 117 TNBC (17.7%)	NS	NLR as prognostic for DFS and DSS	1.34	+ NLR and DFS (RR = 1.18; $p < 0.001$ ) + NLR and DSS (RR = 1.27; $p < 0.001$ )	- NLR and DFS (RR = 1.24; $p = 0.613$ ) - NLR and BCSS (RR = 1.24; $p = 0.681$ )
Ferroni 2018	<b>475 patients</b> including 164 luminal A (35%) 239 luminal B (50%) 15 Her2 positive (3%) 57 TNBC (12%)	NACT for 14.1% adjuvant therapy for 82.5% (with anthracyclines)	NLR as prognostic factor for DFS and OS	2	+ NLR and DFS (HR= 2.28 ; $p = 0,001$ ) + NLR and OS (HR = 3.39; $p = 0,050$ )	
Geng 2018	<b>1374 patients</b> in testing group including 1038 Hormone receptor + (75.6%) 336 Hormone receptor - (24.4%) 128 Her2 positive (9.3%) 1246 Her2 negative (90.7%) 208 TNBC (15.1%) 1166 No TNBC (84.9%)	96 patients of cohort 1 had NACT	NLR as prognostic factor for DFS	1.878 (in testing group)	+ NLR and DFS testing group (HR = 2.89; $p < 0.001$ )	+ NLR and DFS in testing group (HR = 2.99; $p < 0.001$ )

Table 3 (continued)

Author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objective (univariate analysis)	Results on multivariate model
Geng 2018	<b>1084 patients</b> in validation group 702 Hormone receptor + (64.7%) 382 Hormone receptor - (35.3%) 170 Her2 positive (15.7%) 914 Her2 negative (84.3%) 212 TNBC (19.6%) 872 No TNBC (80.4%)	NS	NLR as prognostic factor for DFS	1.878 (based on testing group)	+ NLR and DFS in validation group (HR = 1.65; $p = 0.017$ )	+ NLR and DFS in validation group (HR = 1.64; $p = 0.023$ )
Fujimoto 2018	<b>889 patients</b> including 699 ER+ (78.6%) 152 Her2 positive (17.1%)	Adjuvant CT for 29.6%	NLR as prognostic factor for DFS	2.72	+ NLR and DFS (HR = 1.56; $p = 0.047$ ) - NLR and OS ( $p = 0.23$ )	- NLR and DFS ( $p = 0.14$ )
Kim 2016	<b>220 patients</b> with pN3 BC including 99 Hormone receptor +/Her2 - (45%) 44 Hormone receptor+/Her2 + (20%) 48 Hormone receptor-/Her2 + (21.8%) 29 TNBC (13.2%)	Adjuvant CT (anthracyclines followed by taxanes) for all patients	NLR as prognostic factor for DFS	3 (from previous studies)	+ NLR and 5y-DFS ( $p = 0.043$ )	+ NLR and DFS (HR = 3.93; $p = 0.020$ )
Qiu 2018	406 TNBC patients	NACT (21.2%) Adjuvant CT (78.8%)	NLR as prognostic factor for DFS and OS	2.85	+ NLR and DFS (HR = 2.63; $p < 0.001$ ) + NLR and OS (HR = 3.26; $p < 0.001$ )	+ NLR and DFS (HR = 2.13; $p = 0.008$ ) + NLR and OS (HR = 2.69; $p = 0.001$ )
Pistelli 2015	90 TNBC patients	NS	NLR as prognostic factor for DFS	3	+ NLR and DFS ( $p = 0.002$ ) + NLR and OS ( $p = 0.003$ )	+ NLR and DFS (HR = 5.15; $p = 0.03$ ) + NLR and OS (HR = 6.16; $p = 0.01$ )
Lee 2019	358 TNBC patients	Adjuvant CT (86.6%) : anthracyclines (50.9%), anthracyclines + taxanes (22.4%), others (26.7%) NACT (14%): anthracyclines + taxanes (64%), anthracyclines (36%)	NLR as prognostic factor for DFS and OS	3.16	+ NLR and DFS (HR = 2.11; $p = 0.036$ ) + NLR and OS (HR = 2.97; $p = 0.003$ )	- NLR and DFS ( $p = 0.14$ ) + NLR and OS (HR = 3.15; $p = 0.009$ )
Patel 2019	126 TNBC patients	NACT (31.7%) or adjuvant CT (52.4%) or both (4.8%)	NLR as prognostic factor for DFS and OS	NLR: 3 (based on previous studies)	- NLR baseline and DFS ( $p = 0.77$ ) - NLR baseline and OS ( $p = 0.23$ )	
Liu 2016	318 HR negative patients including 157 Her2 positive (49.4%) 161 Her2 negative (50.6%)	adjuvant CT (81.5%) or NACT (17.6%) or none (0.9%)	NLR as prognostic	3	+ NLR and DFS (HR = 2.37; $p < 0.001$ ) + NLR and OS (HR = 3.09; $p < 0.001$ )	+ NLR and DFS (HR = 1.89; $p < 0.001$ ) + NLR and OS (HR = 3.09; $p < 0.001$ )

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease free survival, OS: overall survival, CT: chemotherapy, NACT: neoadjuvant chemotherapy, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer, TNBC : triple negative breast cancer

### 3.1.1.2.1 Results on DFS

#### 3.1.1.2.1.1 Studies including all molecular subtypes

Seventeen studies had analysis on DFS (33–47). In univariate analysis, 82% of them (N = 14) reported that NLR was correlated with DFS (34,35,37–42,44–46,46,47). Thirteen papers reported results with multivariate models (34,35,37–42,44,46–48) and 8 of them (61.5%) showed that NLR was an independent prognostic factor for DFS (34,37–40,46,48).

#### 3.1.1.2.1.2 Studies with specific molecular subgroups

Four studies reported data on patients with TNBC (49–52). Three out of four (75%) showed that high NLR was correlated to shorter DFS in univariate analyses (49–51). In multivariate analyses two studies showed a statistically significant correlation between NLR and DFS in TNBC patients receiving adjuvant CT (49,50).

Liu *et al* (53) studied patients with hormone receptor negative BC. They found a correlation between NLR and DFS as well in univariate than in multivariate analysis (HR = 1.89; 95%CI 1.42-2.51;  $p < 0.001$ ).

#### 3.1.1.2.1.3 Subgroup analyses

Many studies reported subgroup analyses based on stage, molecular or pathological subtypes. Five studies tried to differentiate if results were different according to molecular subtypes (32,38,39,44,46). Cho *et al* (44) found that NLR was correlated with DFS (and to disease specific survival) only in luminal cancer; Noh *et al* (32) found the same results for luminal A cancer; whereas for Hong *et al* and for Jia *et al* (38,39) NLR was correlated with DFS only in TNBC. Finally, in Geng *et al* subgroup analyses (46), correlation between NLR and DFS was found for all molecular subtypes.

Cho *et al* showed that in patients with lymph node invasion, NLR was correlated to DFS, but only in univariate analysis (44).

Two authors (45,46) showed that NLR was correlated to DFS in early stage (I and/or II according to AJCC) but not in stage III BC.



### *3.1.1.2.2 Results on OS and BCSS*

#### *3.1.1.2.2.1 Studies including all molecular subtypes*

Ten studies reported data on NLR and OS in patients receiving adjuvant treatment (33,34,36–39,41,42,45,47). Out of them, 6 (60%) found a correlation in univariate analysis (34,36,37,39,41,45).

Five authors had multivariate analyses on NLR and OS (34,36,37,39,41) and 4 of them (80%) found that NLR was an independent prognostic factor for OS (34,36,37,39).

Three studies reported data on NLR and BCSS (32,35,44). All of them showed correlation between these two factors in univariate analyses and two out of three (66%) showed that NLR was an independent prognostic factor for BCSS (32,35).

#### *3.1.1.2.2.2 Studies including specific molecular subtypes*

Four studies reported data on patients with TNBC and studied OS according to NLR (49–52). Three out of four (75%) showed that high NLR was correlated to shorter OS in univariate analysis (49–51). In multivariate analysis three studies (out of three) showed a statistically significant correlation between NLR and OS in TNBC patients receiving adjuvant CT (49–51).

Liu *et al* studied patients with hormone receptor negative BC (53). They found a correlation between NLR and OS as well in univariate than in multivariate analyses (HR = 3.09; 95%CI 2.35-4.06;  $p < 0.001$ ).

#### *3.1.1.2.2.3 Subgroup analyses*

Yao *et al* (36) found that luminal A and TNBC were the two intrinsic subtypes in which NLR is correlated to OS, whereas Jia *et al* (39) found that NLR is correlated to OS only in the TNBC subgroup.

### *3.1.1.2.3 Conclusion on NLR as prognostic factor in patients receiving adjuvant treatment*

Twenty three papers reported data on NLR as prognosis factor in patients receiving adjuvant treatment (32–53). In those papers a total of 29 multivariate analyses were conducted and 21 one of them (72.4%) report a correlation between NLR and survival (32,34–40,46,48–51,53). Eleven out of 17 analyses (65%) found a positive correlation between NLR and DFS (34,37–40,46,48–50,53), 8 out of 9 analyses (89%) found a positive correlation between NLR and OS (34,36,37,39,49–51,53) and 2 out of 3 analyses (66%) found a positive correlation between NLR and BCSS (32,35). A total of 18 153 patients were enrolled in these studies. Table 4 summarizes multivariate analyses and adjustment factors.

Table 4: Multivariate models (results and adjustment factors) for patients receiving adjuvant treatment

All molecular subtypes				
	DFS	OS	BCSS	Total
Number of multivariate models	13	5	3	21
Number of unique patients	9333	4597	1879	15809
NLR significantly associated with n(%)	8 (61.5%)	4 (80%)	2 (66%)	14 (66%)
Adjustment factor (%)				
T	77	80	33	
N	70	60	100	
AJCC stage	38	40	NI	
Age	31	20	67	
Menopausal status	23	NI	NI	
Hormone receptors	23	NI	67	
Her2 status	8	NI	NI	
Molecular subtype	54	80	NI	
Histological grade	38	20	NI	
LVI	8	NI	33	
Perineural invasion	NI	NI	33	
Ki67	8	NI	NI	
Multifocality	8	NI	NI	
Adjuvant CT	15	20	NI	
Endocrine therapy	8	NI	NI	
Use of NSAIDS	8	20	NI	
PLR	15	40	33	
LMR	15	20	33	
MCH	8	NI	NI	
RDW	NI	20	NI	
dNLR	8	NI	33	
TNBC				
	DFS	OS		Total

Number of multivariate models	3	3		6
Number of unique patients	854	854		1708
NLR significantly associated with n(%)	2 (66%)	3 (100%)		5 (83%)
Adjustment factor (%)				
T	67	67		
N	67	67		
AJCC stage	33	33		
Age	100	67		
Menopausal status	33	33		
Histological subtype	33	33		
Histological grade	67	67		
Ki67	33	67		
Necrosis	33	33		
LVI	67	67		
Type of surgery	33	33		
Adjuvant CT (vs NACT)	33	33		
Adjuvant radiotherapy	33	33		
Cancer recurrence	NI	33		
<b>HR negative</b>				
	DFS	OS		Total
Number of multivariate models	1	1		2
Number of unique patients	318	318		636
NLR significantly associated with n(%)	1 (100%)	1 (100%)		2 (100%)
Adjustment factor (%)				
T	100	100		
N	100	100		
Age	100	100		
Histological grade	100	100		
Her 2 status	100	100		
PLR	100	100		
<b>All studies</b>				
	DFS	OS	BCSS	Total
Number of multivariate models	17	9	3	29
Number of unique patients	10505	5769	1879	18153
NLR significantly associated with n(%)	11 (65%)	8 (89%)	2 (66%)	21 (72.4%)

CT: chemotherapy, DFS: disease free survival, OS: overall survival, BCSS: breast cancer specific survival, NLR: neutrophil to lymphocyte ratio, NSAIDs: non-steroidal anti-inflammatory drugs, LMR: lymphocyte to monocyte ratio, MCH: mean corpuscular hemoglobin, NMR: neutrophil to monocyte ratio, RDW: red cell distribution width, dNLR: derived NLR, PLR: platelet to lymphocyte ratio, LVI: lympho-vascular invasion, NACT: neoadjuvant chemotherapy, NI: not indicated

#### 3.1.1.2.4 Results on other IBM

Eleven studies reported results on IBM other than NLR. PLR was found to be correlated to DFS in 4 analyses (41,43,44,53) out of six (66.6%) studying this

correlation (33,36,41,43,44,53) and to OS in two analyses (41,53) out of 4 (50%) studying this correlation (33,36,41,53). It was found to be correlated to DSS in Cho *et al*'s work (44). Four authors (41,43,44,53) reported data on PLR with multivariate analyses and 75% of them found that PLR was an independent prognosis factor for DFS (41,43,44), 50% (one out of two) found a correlation between PLR and OS (41) and 100% for DSS (but it was reported in only one study) (44).

Two studies reported data on dNLR (derived NLR, calculated as neutrophil over white blood cells [WBC] minus neutrophils) and both found correlation between dNLR and DFS or OS or DSS in univariate analyses (37,44) but not in multivariate analyses (44).

Jia *et al* (39), Takeuchi *et al* (43) and Cho *et al* (44) studied LMR as prognosis factor. Jia *et al* and Cho *et al* found a correlation between LMR and DFS, OS and DSS in univariate analysis. In multivariate analyses, no correlation was found between LMR and survival.

Lymphocyte count and survival was studied in 4 papers (33,44,47,52). Lymphocyte count was correlated to DFS only in one analysis out of 4 (25%) (44), was never found to be correlated to OS and was found to be correlated to DSS in one analysis (25%) (44). No authors did multivariate analyses on lymphocyte count and survival.

Finally, two authors (33,44) showed that there was no correlation between neutrophil count, platelet count, monocyte count and survival. Cihan *et al* (33) also reported no correlation between white blood cell count, eosinophil cell count, basophil cell count and survival in univariate analyses.

### 3.1.2 Patients with advanced breast cancer (Table 5)

We identified 8 studies that reported data on NLR as prognostic factor in metastatic BC patients (54–61). Four articles (50%) studied cancer of all molecular subtypes (54,56–58), two focused on Her2 positive patients (55,61), one on TNBC (60) and one on hormone receptor positive patients receiving hormone therapy as initial drug therapy (59).

Table 5: Articles including data on NLR as prognosis factor in metastatic breast cancer patients

Author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objectives (univariate analysis)	Results on multivariate models
Iwase 2017	<b>89 patients</b> with recurrent BC following surgery including 31 ER+ Her2- (35%) 20 ER+ Her2+ (22%) 14 Her2 type (16%) 24 TNBC (27%)	NS	NLR and prognosis	3 (based on previous studies)	+ NLR and OS (HR =2 .68; $p < 0.05$ )	+ NLR and OS (HR = 2.93; $p > 0.05$ )
Araki 2018	<b>51 Her2 positive patients</b> including 14 ER+ (47%) 5 PR+ (17%)	pertuzumab and trastuzumab combined with eribuline (ERI) (n=30) or nab-paclitaxel (Nab-PTX) (n=21)	blood based parameters prognostic	NLR: 2 (median values)	- NLR and PFS	
Miyagawa 2018	<b>85 patients</b> including 62 ER+ (73%) 39 PR+ (46%) 4 Her2 positive (5%)	eribulin (n=59) or nab-paclitaxel (n=26)	NLR and prognosis according to treatment administrated	3 based on previous studies	+ NLR and PFS eribulin group (HR = 0.37; $p = 0.003$ ) - NLR and PFS in nab-paclitaxel group ( $p = 0.84$ ) - NLR and OS eribulin group ( $p = 0.058$ ) - NLR and OS in nab-paclitaxel group ( $p = 0.15$ )	+ NLR and PFS in eribulin group (HR = 0.39; $p = 0.007$ )
De Sanctis 2018	<b>71 patients</b> including 53 hormone receptor+ (75%) 8 Her2 positive (11%) 11 TNBC (15%)	eribulin (after 2 to 5 previous lines of CT)	NLR as prognostic factor	2,5-4-5,5	- NLR and PFS ( $p > 0,5$ ) for any cut off	
Takuwa 2018	171 patients including 93 ER+ Her2 negative (54.4%) 23 ER+ Her2 positive (13.5%) 20 ER- Her2 positive (11.7%) 28 ER- Her2 negative (16.4%) 7 unknown (4.0%)	NS	NLR as prognostic factor	1.9	+ NLR and OS (33 vs 79 months, $p = 0.004$ )	+ NLR and OS (HR = 1.75; $p = 0.022$ )

Table 5 (continued)

Author	Number of patients	Treatment received	Primary objective	Cut off	Results on primary objectives (univariate analysis)	Results on multivariate models
limori 2018	<b>34 patients</b> receiving ET as initial drug therapy including 4 Her2 positive (12%)	Endocrine therapy: letrozole (58.8%); anastrozole (20.6%); tamoxifen (with/without LHRH) (17.7%); exemestane (2.9%)	NLR predictive of response to endocrine therapy and prognosis	3 based on previous studies	+ NLR and PFS (HR = 3.94; $p = 0.016$ ) + NLR and OS ( $p = 0.013$ ) + NLR and time to treatment failure ( $p = 0.031$ )	+NLR and PFS (HR = 3.93; $p = 0.008$ )
Vernieri 2018	<b>57 TNBC</b> patients	Platinum based CT: Carboplatin-taxol (84%) or carboplatin-gemcitabin (16%) First line (88%) or second line (12%)	NLR as prognostic factor	2.5 based on previous studies	+ NLR and PFS (HR = 3.25; $p < 0.001$ )	+ NLR and PFS (HR = 2.65; $p = 0.004$ )
Imamura 2019	<b>53 Her2 positive</b> patients	TDM-1	NLR as prognostic factor	2,56	+ NLR and PFS (HR = 0.23; $p < 0.001$ ) + NLR and OS (HR = 0.38; $p = 0.0296$ )	+ NLR and PFS (HR = 0.27; $p = 0.0019$ ) + NLR and OS (HR = 0.35; $p = 0.018$ )

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease free survival, OS: overall survival, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer, ET: endocrine therapy, TNBC: triple negative breast cancer

For NLR, the cut off was set between 1.9 and 3 (for all of the studies, the cut off value was based on previous studies). Number of patients enrolled in each study varied between 34 and 171. Six studies (75%) reported data on Asian populations (54–56,58,59,61).

### *3.1.2.1 Results on PFS*

#### *3.1.2.1.1 Studies including all molecular subtypes*

Two studies reported data on NLR and PFS (56,57) and one of them (50%) showed that NLR was an independent prognostic factor for PFS (HR = 0.39; 95%CI 0.18-0.78;  $p < 0.001$ ) (56).

#### *3.1.2.1.2 Studies including only specific molecular subtypes*

Vernieri *et al* (60) studied TNBC subtype and found that NLR was an independent prognostic factor for PFS for their population of 57 patients (HR = 2.65; 95%CI 1.36-5.18;  $p = 0.004$ ).

In the two papers interested in patients with Her2 positive tumors (55,61), only one of them found a correlation between NLR and PFS in multivariate analysis (HR = 0.27; 95%CI 0.10-0.63;  $p < 0.001$ ) (61).

Limori *et al* (59) found that NLR was an independent prognostic factor for PFS in their population of patients with hormone receptor positive BC receiving endocrine therapy as initial drug therapy (HR = 3.93; 95%CI 1.4-10.84;  $p = 0.008$ ).

### *3.1.2.2 Results on OS*

#### *3.1.2.2.1 Studies including all molecular subtypes*

Three studies reported data on NLR and OS (54,56,58) and two of them (66%), written by Iwase *et al* (54) and Takuwa *et al* (58) found that NLR was an independent prognostic factor for OS in patients with metastatic BC.

#### *3.1.2.2.2 Studies including only specific molecular subtypes*

Imamura *et al* (61) studied NLR and OS in patients with Her2 positive BC and found a correlation between these two factors in univariate and multivariate analyses (HR = 0.35; 95%CI 0.13-0.84;  $p = 0.018$ ).

limori *et al* (59) conducted the same analysis on patients with hormone receptor positive BC and found a correlation in univariate analysis (multivariate results not available).

### 3.1.2.3 Conclusion on NLR as prognostic factor in patients with advanced breast cancer

Six articles reported data with multivariate analyses on patients with advanced BC (54,56,58–61). All (6 out of 6) of the studies analyzing NLR and survival found a significant correlation between these two factors. Data should be handling carefully since not all the studies had multivariate analyses and the populations are very heterogeneous. Table 6 summarizes results on multivariate analyses and adjustment factors.

Table 6: Multivariate models (results and adjustment factors) for patients treated for advanced BC

All molecular subtypes			
	PFS	OS	Total
Number of multivariate models	1	2	3
Number of unique patients	85	260	345
NLR significantly associated with n(%)	1 (100%)	2 (100%)	3 (100%)
Adjustment factor (%)			
Menopausal status	NI	50	
BMI	NI	50	
Molecular subtype	NI	50	
LDH	NI	50	
Complete response	NI	50	
Primary stage IV	NI	50	
Number of metastatic sites	NI	50	
Visceral metastasis sites ( $\geq 2$ vs $<2$ )	NI	50	
Previous CT	100	NI	
HR +			
	PFS		Total
Number of multivariate models	1		1
Number of unique patients	34		34
NLR significantly associated with n(%)	1 (100%)		1 (100%)
Adjustment factor (%)			
Objective response to endocrine therapy	100	NI	
TNBC			



	PFS		Total
Number of multivariate models	1		1
Number of unique patients	57		57
NLR significantly associated with n(%)	1 (100%)		1 (100%)
Adjustment factor (%)			
Visceral metastasis	100	NI	
Maintenance CT	100	NI	
Previous exposure to taxanes	100	NI	
PLR	100	NI	
<b>Her 2 positive</b>			
	PFS	OS	Total
Number of multivariate models	1	1	2
Number of unique patients	53	53	106
NLR significantly associated with n(%)	1 (100%)	1 (100%)	2 (100%)
Adjustment factor (%)			
Disease control during 1st line	100	100	
Number of metastatic sites	100	100	
<b>All patients</b>			
	PFS	OS	Total
Number of multivariate models	4	3	7
Number of unique patients	229	313	542
NLR significantly associated with n(%)	4 (100%)	3 (100%)	7 (100%)

CT: chemotherapy, PFS: progression free survival, OS: overall survival, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, BMI: body mass index, NI: not indicated

#### 3.1.2.4 Results for other IBM

Three articles had data on other IBM as prognostic factors for survival in advanced BC (55,60,61). In univariate analysis, PFS was related to ALC, to PLR and to LMR in some analysis (55,60), but contradictory results showed no correlation between PLR and PFS (61). Vernieri *et al* (60) reported multivariate analysis and found that PLR was an independent prognostic factor for PFS. One analysis showed that PLR was not a prognostic factor for OS (61).

### 3.2 Toxicity (Table 7)

We identified 4 articles that reported data on IBM and treatment-related toxicity (62–65) as primary objective. Only one study analyzed the relation between NLR and toxicity in a cohort of BC (Yamanouchi *et al* (65)). The three others were interested in lymphopenia (defined as

lymphocytes value  $< 0.7$  G/L) in a cohort of different cancer types (including BC). Two studies evaluated a French population (62,63), while the 2 other ones focused on Asian patients (64,65).

In 2001, Ray Coquard *et al* (62) studied predictive factors for early death after CT (defined as death within one month after the administration of cancer CT) in a prospective study and found, in a group of 1051 patients with different types of cancer (including 756 [33%] BC patients), that lymphocyte count at day 1  $< 0.7$  G/L was predictive for early death cancer as well in univariate than in multivariate models (OR = 3.1 ; 95%CI 1.8-5.8;  $p < 0.001$ ).

The same authors published a second article in 2003 (63) where they evaluated if lymphocyte count  $< 0.7$  G/L at day 1 was predictive for febrile neutropenia (FN). They evaluated three cohorts of patients (including the cohort used for their previous work) accounting for 950, 321 and 329 patients, of whom 24%, 33% and 42% of them were affected by BC, respectively. They found that, in the largest cohort of patients, lymphocyte count  $< 0.7$  G/L at day one was predictive for FN in univariate and multivariate analyses (OR = 1.75; 95%CI 1.49-4.8;  $p = 0.02$ ).

A Korean study, written by Choi *et al* (64), performed the same evaluation in a group of 82 patients (including 11 [13%] BC patients) receiving their first course of CT. They found no correlation between lymphopenia at day one and risk of FN. However, considering the limited number of BC patients in this series, no definitive conclusion could be drawn from this publication.

Yamanouchi *et al* (65) were the only ones to study, in a cohort of 67 patients with BC, the relationship between peripheral neuropathy and NLR, PLR or MLR in patients receiving at least 4 cycles of docetaxel ( $75 \text{ mg/m}^2$ ). They found no correlation between these three IBM and the occurrence of peripheral neuropathy.

Table 7: Articles including data on IBM as predictive factor of toxicity in breast cancer patients

Author	Number of patients	Population of interest	Treatment received	Primary objective	Cut off	Results on primary objective (univariate results)	Results on multivariate model
Ray Coquard 2001	1051	first line CT all cancers (BC, colon, ovary, head and neck, lung, other)	NS	to establish a risk model for early death after CT (defined as death within a month after the administration of CT)	lymphocytes < 0.7 G/L	predictive of early death: day 1 lymphocyte count < 0.7 G/L ( $p < 0.01$ ) day 1 platelet count < 150 G/L ( $p = 0.01$ )	predictive of early death: d1 lymphocytes < 0.7 G/L (OR = 3.1)
Ray Coquard 2003	3 groups : -950 patients in groupe CLM-1996 - 321 patients in Elypse 1 - 329 patients in Elypse 0	all cancers (BC, colon-rectum, ovary, head and neck, lung, lymphoma, myeloma, sarcomas, germ cells tumors, others) receiving CT (regardless of previous course)	NS	to investigate a risk model for FN using only day 1 blood cell count and to compare the day 1 and day 5 risk model	lymphocytes < 0.7 G/L	in CLB-1996 cohort: + lymphocytes d1 and FN ( $p = 0.05$ ) lymphocytes d5 and FN data not available in Elypse 1 cohort: - lymphocytes d1 and FN ( $p = 0.18$ ) + lymphocytes d5 and FN ( $p < 0.01$ ) in Elypse 0 cohort: - lymphocytes d1 and FN ( $p = 0.08$ ) + lymphocytes d5 and FN ( $p < 0.01$ )	lymphocytes d1 and FN (OR = 1.75; $p = 0.02$ )
Choi 2003	82	all cancers (non Hodgkin lymphoma, stomach cancer, BC, NSCLC, hepatobiliary cancer, sarcoma, colorectal cancer and others) receiving first course of CT	NS	to evaluate lymphocyte count at day 1, day 3 and day 5 as a way to identify patients at risk of FN	lymphocytes < 0.7 G/L and lymphocytes < 0.5 G/L	for lymphocytes $\leq 0,5$ G/L: - d1 and FN ( $p = 0.33$ ) + d3 and FN ( $p < 0.01$ ) + d5 and FN ( $p = 0.023$ ) for lymphocytes $\leq 0,7$ G/L: - d1 and FN ( $p = 0.05$ ) + d3 and FN ( $p = 0.01$ ) + d5 and FN ( $p < 0,01$ )	d5 lymph $\leq 0,7$ G/L and NF (OR = 19.0 $p = 0.01$ )
Yamanouchi 2017	67	BC, all stages (only 6% stage IV)	Docetaxel 75 mg/m <sup>2</sup> at least 4 cycles	to elucidate the relationship between peripheral neuropathy (PN) and NLR, PLR and MLR	median NLR of patients with or without toxicity analyzed	no correlation between the NLR, PLR, or MLR before or at the first or third cycle and the occurrence of PN	

CT: chemotherapy, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, MLR: monocyte to lymphocyte ratio, OR: odd ratio, BC: breast cancer, FN: febrile neutropenia, PN: peripheral neuropathy

#### 4. CONCLUSION

We report here a comprehensive, exhaustive overview of the published literature regarding NLR as a predictive and / or prognostic factor in BC patients.

NLR appears to be a reliable prognostic factor in the adjuvant BC setting, since 21 analyses out of 29 (72.4%) with reported multivariate data found an independent correlation between NLR and survival (DFS, BCSS and / or OS) (32,34–40,46,48–51,53).

Results are more controverted for patients with localized disease receiving NACT since only two studies out of four (50%) found a correlation between NLR and DFS (25,30) and one study out of two (50%) found a correlation between NLR and OS (30). The only study that analyzed NLR and BCSS found a significant correlation (25). In the same NACT-treated population, conclusions on NLR and PCR can't be established since only one study out of two (50%) found a correlation between these two factors (31). Some heterogeneity in the impact of NLR in this setting could be linked to variable impacts of this factor based on molecular subtypes, as the only positive study evaluated only TNBC patients.

This lack of significant association in the NACT setting could be also linked to analyses with smaller populations. Indeed, the total number of patients enrolled in selected studies analyzing NACT was 1558 *versus* 18153 patients analyzed in studies focusing on patients with early BC receiving adjuvant treatment.

Fewer data have been published for patients with metastatic BC, but NLR appears to be a good prognostic factor for PFS and OS in this population, although studies are hard to compare since the population are very heterogeneous (54,56,58–61). Population of interest was different for each study analyzed, either by the molecular features of BC analyzed or by the treatment received or by the number of previous lines of CT received before. Therefore, no conclusion can be made on IBM as prognosis factor in patients with metastatic BC.

Only very few studies are focused on NLR or lymphopenia as predictive factor of CT-related toxicity (62–65). Lymphopenia at day one appears to be correlated with early death after CT (62), but no definitive conclusion could be made for BC patients since the population studied included various cancer types, and no specific subgroup analysis has been performed in the BC subgroup. Lymphopenia at day one was inconsistently correlated to febrile neutropenia

(two studies diverge on results (63,64)) and NLR was not correlated to peripheral neuropathy in patients receiving docetaxel (65). Other studies with larger population should be conducted in order to have more data on NLR or lymphopenia as predictive factor for toxicity.

Considering its worse prognosis and better chemosensitivity, TNBC has been the molecular subgroup the most extensively evaluated, as, out of the studies that we compared in this review, subgroup analyses on TNBC have been reported in 10 analyses (23,24,32,36,38,39,46,53,56). Most of them (80%) found a correlation between NLR and survival in this specific sub group (23,36,38,39,46,53,56), a proportion of positive articles higher than reported in the other subgroups, possibly related to the TNBC specific clinical history.

It is noteworthy, in this overview of the published literature, that majority of the selected studies (33/41) were evaluating a population of Asian patients (23,25,28,30–32,35,36,38,39,42–44,46–49,51,53–56,58,59,61,64,65). This demographic variable could be associated with specific molecular and pharmacological features that can induce differences in toxicity and efficacy profiles. Another limitation is linked to the HER2 population, where the notion of anti-HER2 targeted therapy use is inconsistently reported, inducing heterogeneity in survival expectations. Considering these population-based sources of confusion, a large, multi-ethnic study appears mandatory in order to evaluate, worldwide and part of the world by part of the world, the prognostic and predictive value of NLR and other IBM in BC patients.

Another limitation comes from the drugs used in the neoadjuvant or adjuvant regimens as, although most of the studies reported the use of anthracyclines and /or taxanes, only a minority of them (16 out of 34, 47%) declared to use sequential or concomitant anthracyclines and taxanes-based regimens, presently recommended by the international societies. Data on CT regimen were missing for many studies (18 out of 34, 53%).

Lastly, one must keep in mind that the selected studies were retrospective. Even if most of them (> 75%) reported at least one multivariate model in order to reinforce their results, a prospective validation, or the retrospective evaluation in a prospective clinical trial, of these results appears necessary.

In conclusion, NLR appears to be a prognostic factor for DFS and OS in patients with early BC receiving adjuvant CT. Further investigations with prospective studies would help to reinforce

these results. For NACT the correlation between NLR and survival remains unclear since most of the studies failed to show an evidence of independent correlation. Finally, most of the available data show that NLR is not a predictive factor for PCR in patients treated with NACT, however, due to the heterogeneity and / or small sample size of the published data on this topic, dedicated studies are needed.

## BIBLIOGRAPHY

1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol Off J Eur Soc Med Oncol*. 2019 Jun 4;
2. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)<sup>†</sup>. *Ann Oncol*. 2018 Aug 1;29(8):1634–57.
3. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. *J Cancer*. 2018;9(5):861–71.
4. Xue LB, Liu YH, Zhang B, Yang YF, Yang D, Zhang LW, et al. Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. *Medicine (Baltimore)*. 2019 Jan;98(1):e13842.
5. Mouchemore KA, Anderson RL, Hamilton JA. Neutrophils, G-CSF and their contribution to breast cancer metastasis. *FEBS J*. 2018;285(4):665–79.
6. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. *Cell*. 2010 Mar 19;140(6):883–99.
7. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity*. 2019 Jul 16;51(1):27–41.
8. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*. 2009 Jul;30(7):1073–81.
9. Swierczak A, Mouchemore KA, Hamilton JA, Anderson RL. Neutrophils: important contributors to tumor progression and metastasis. *Cancer Metastasis Rev*. 2015 Dec;34(4):735–51.
10. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer*. 2016 Jul;16(7):431–46.
11. Ou Q, Cheng J, Zhang L, Wang H, Wang W, Ma Y. The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous? *Tumour Biol J Int*

Soc Oncodevelopmental Biol Med. 2017 Jun;39(6):1010428317706214.

12. Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, et al. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. *Tumour Biol J Int Soc Oncodevelopmental Biol Med*. 2017 Apr;39(4):1010428317695023.

13. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 2010 Jan 1;28(1):105–13.

14. Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. *Ann Surg Oncol*. 2015 May;22(5):1441–6.

15. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet Lond Engl*. 2014 Jul 12;384(9938):164–72.

16. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. *FEBS Open Bio*. 2015;5:502–7.

17. Faria SS, Fernandes PC, Silva MJB, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedicalscience*. 2016;10:702.

18. Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. *OncoTargets Ther*. 2016;9:5567–75.

19. Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res BCR*. 2017 05;19(1):2.

20. Liu X, Qu J-K, Zhang J, Yan Y, Zhao X-X, Wang J-Z, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. *Medicine (Baltimore)*. 2017 Nov;96(45):e8101.

21. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. *Medicine (Baltimore)*. 2018 Dec;97(49):e13340.

22. Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The Neutrophil to



Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. *Asian Pac J Cancer Prev.* 2014 Oct 11;15(18):7737–40.

23. Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. *Ann Surg Oncol.* 2016;23:1104–10.

24. Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, et al. Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. *BMC Cancer* [Internet]. 2015 Dec 29 [cited 2019 Apr 11];15. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696229/>

25. Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. *BMC Cancer.* 2016 19;16:320.

26. Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, Galindo Fernández PJ, Ruiz Merino G, Alonso Romero JL, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. *Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex.* 2018 Apr;20(4):476–83.

27. Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. *The Breast.* 2019 Apr;44:33–8.

28. Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J, et al. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. *OncoTargets Ther.* 2018;11:1423–32.

29. Losada B, Guerra JA, Malón D, Jara C, Rodriguez L, Del Barco S. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. *Clin Transl Oncol* [Internet]. 2018 Nov 30 [cited 2019 Apr 28]; Available from: <http://link.springer.com/10.1007/s12094-018-1999-9>

30. Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G. Prognostic significance of the ratio of absolute

neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. *Tumor Biol.* 2014 Oct;35(10):9823–30.

31. Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, et al. Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. *Curr Oncol.* 2018 Apr;25(2):e113–9.

32. Noh H, Eomm M, Han A. Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. *J Breast Cancer.* 2013 Mar;16(1):55–9.

33. Cihan YB, Arslan A, Cetindag MF, Mutlu H. Lack of Prognostic Value of Blood Parameters in Patients Receiving Adjuvant Radiotherapy for Breast Cancer. *Asian Pac J Cancer Prev.* 2014 May 30;15(10):4225–31.

34. Forget P, Bentin C, Machiels J-P, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. *Br J Anaesth.* 2014 Jul;113:i82–7.

35. Nakano K, Hosoda M, Yamamoto M, Yamashita H. Prognostic Significance of Pre-treatment Neutrophil: Lymphocyte Ratio in Japanese Patients with Breast Cancer. *Anticancer Res.* 2014 Jan 7;34(7):3819–24.

36. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. *OncoTargets Ther.* 2014 Sep 26;7:1743–52.

37. Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? *Int J Clin Oncol.* 2015 Feb;20(1):70–81.

38. Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, et al. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. *Tumor Biol.* 2016 Mar;37(3):4135–42.

39. Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. *PLoS ONE [Internet].* 2015 Nov 18 [cited 2019 Apr 28];10(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666347/>

40. Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. *ESMO Open* [Internet]. 2016 Mar 7 [cited 2019 Apr 28];1(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070254/>
41. Ramos-Esquivel A, Rodriguez-Porras L, Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. *Breast Dis*. 2017 Jan 1;37(1):1–6.
42. ZHANG P, ZONG Y, LIU M, TAI Y, CAO Y, HU C. Prediction of outcome in breast cancer patients using test parameters from complete blood count. *Mol Clin Oncol*. 2016 Jun;4(6):918–24.
43. Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. *PLoS ONE* [Internet]. 2017 May 10 [cited 2019 Apr 28];12(5). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425200/>
44. Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. Lafrenie RM, editor. *PLOS ONE*. 2018 Jul 26;13(7):e0200936.
45. Ferroni P, Roselli M, Buonomo OC, Spila A, Portarena I, Laudisi A, et al. Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. *Anticancer Res*. 2018 Jan 8;38(8):4705–12.
46. Geng S-K, Fu S-M, Fu Y-P, Zhang H-W. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection. *Medicine (Baltimore)* [Internet]. 2018 Aug 21 [cited 2019 Apr 28];97(35). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392639/>
47. Fujimoto Y, Ozawa H, Higuchi T, Miyagawa Y, Bun A, Imamura M, et al. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. *Mol Clin Oncol*. 2019 Feb;10(2):275–84.
48. Kim YY, Park HK, Lee KH, Kim KI, Chun YS. Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer. *J Breast Cancer*. 2016 Jun;19(2):163–8.

49. Qiu X, Song Y, Cui Y, Liu Y. Increased neutrophil–lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients. *IUBMB Life*. 2018 Jun 1;70(6):529–35.
50. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. *BMC Cancer* [Internet]. 2015 Mar 28 [cited 2019 Apr 28];15. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428113/>
51. Lee J, Kim D-M, Lee A. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. *Cancer Res Treat Off J Korean Cancer Assoc*. 2019 Apr;51(2):649–63.
52. Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, et al. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. *Breast Cancer Res Treat*. 2019 Apr;174(2):443–52.
53. Liu C, Huang Z, Wang Q, Sun B, Ding L, Meng X, et al. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. *OncoTargets Ther*. 2016 Jul 27;9:4653–60.
54. Iwase T, Sangai T, Sakakibara M, Sakakibara J, Ishigami E, Hayama S, et al. An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer. *Mol Clin Oncol*. 2017 Feb;6(2):266–70.
55. Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. *BMC Cancer* [Internet]. 2018 Oct 16 [cited 2019 May 2];18. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191898/>
56. Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. *Clin Breast Cancer*. 2018;18(5):400–9.
57. De Sanctis R, Agostinetto E, Masci G, Ferraro E, Losurdo A, Viganò A, et al. Predictive

Factors of Eribulin Activity in Metastatic Breast Cancer Patients. *Oncology*. 2018 Jul;94(Suppl 1):19–28.

58. Takuwa H, Tsuji W, Yamamoto Y, Shintaku M, Yotsumoto F. Low neutrophil-lymphocyte ratio correlates with extended survival in patients with metastatic breast cancer who achieved clinically complete response following multidisciplinary therapy: A retrospective study. *Oncol Lett*. 2018 May;15(5):6681–7.

59. IIMORI N, KASHIWAGI S, ASANO Y, GOTO W, TAKADA K, TAKAHASHI K, et al. Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. *In Vivo*. 2018 May 3;32(3):669–75.

60. Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep [Internet]*. 2018 Jun 7 [cited 2019 May 14];8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992181/>

61. Imamura M, Morimoto T, Egawa C, Fukui R, Bun A, Ozawa H, et al. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. *Sci Rep [Internet]*. 2019 Feb 12 [cited 2019 May 14];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372578/>

62. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. *Br J Cancer*. 2001 Sep;85(6):816–22.

63. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. *Br J Cancer*. 2003 Jan 27;88(2):181–6.

64. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. *Am J Hematol*. 2003;73(4):263–6.

65. Yamanouchi K, Kuba S, Sakimura C, Morita M, Kanetaka K, Kobayashi K, et al. The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer. *Anticancer Res*. 2017 Jan 12;37(12):6947–51.

## Conclusion générale

Ces deux travaux évaluent des marqueurs biologiques de l'inflammation en tant que facteurs pronostiques et / ou prédictifs de réponse histologique à la chimiothérapie ou de risque de toxicité induites par la chimiothérapie. Ces marqueurs sont très intéressants car disponibles facilement en pratique courante et non coûteux. Ils pourraient ainsi nous aider dans la prise de décision quant aux traitements à administrer à nos patients.

Dans notre premier article, qui est une étude rétrospective sur une population de 280 patientes traitées à l'ICM pour un cancer du sein localisé et recevant une chimiothérapie néoadjuvante, nous avons montré en analyse multivariée, que le PLR est un facteur pronostique de survie sans récurrence (HR = 1.91; IC95% = 1.15-3.16 ;  $p = 0.012$ ) ainsi qu'un facteur pronostique de survie globale (HR = 1.83; IC95% = 1.03-3.24 ;  $p = 0.039$ ). Ainsi un PLR élevé au diagnostic prédirait un risque plus élevé de récurrence et de décès. Cette étude montre également qu'un NLR élevé au diagnostic est un facteur prédictif indépendant de neutropénie fébrile au cours de la chimiothérapie (OR = 0.28; IC95% = 0.13-0.58 ;  $p = 0,001$ ). Aucun marqueur biologique de l'inflammation n'a été retrouvé comme prédictif de réponse histologique complète après chimiothérapie néoadjuvante dans la population globale. Lorsque l'on s'intéresse aux sous-groupes moléculaires, il apparaît que chez les patientes ayant un cancer du sein triple négatif (récepteurs hormonaux négatifs et Her2 négatif) un faible taux de leucocytes au diagnostic ( $< 6.75$  G/L) serait prédictif d'une réponse histologique complète. A notre connaissance, nous rapportons ici la deuxième plus grande série évaluant ces marqueurs biologiques de l'inflammation en situation néoadjuvante. Notre population est homogène, avec des patientes ayant reçu les traitements recommandés par les sociétés savantes et nous disposons d'un long suivi de plus de 6 ans. Nos résultats sont cohérents avec ceux de la littérature.

Dans la revue de la littérature nous nous sommes surtout intéressés au NLR, puisque c'est le biomarqueur qui a été le plus étudié. En situation néoadjuvante, tous sous-groupes moléculaires confondus, la majorité des articles ne trouvaient pas de corrélation entre ce ratio et la survie sans récurrence (66%), la survie globale (100%) ou la réponse histologique complète après traitement (100%). Une seule étude retrouvait une relation statistiquement significative entre le NLR et la survie spécifique (100%). En situation adjuvante, la majorité des études (72.4%) mettaient en évidence un lien entre le NLR et la survie (65% pour la survie sans récurrence, 89%

pour la survie globale et 66% pour la survie spécifique). En situation métastatique ou localement avancée, le NLR est un facteur pronostique dans tous les articles retenus (cependant avec des populations de faibles effectifs et très hétérogènes). Enfin, notre revue s'est également intéressée à la capacité de ces biomarqueurs de prédire les toxicités liées à la chimiothérapie. Seuls 4 articles rapportent de telles données et leurs résultats divergent. La lymphopénie (lymphocytes < 0.7 G/L) au diagnostic serait prédictive d'un décès précoce (< 1 mois) après la chimiothérapie et de neutropénie selon les études du Dr Ray Coquard, mais pas selon l'étude de Choi *et col.* Aucun lien n'a pu être démontré entre les marqueurs biologiques de l'inflammation et la survenue d'une neuropathie périphérique après un traitement par docetaxel.

Pour pouvoir conclure quant à la validité clinique et l'utilité clinique de ces biomarqueurs de l'inflammation dans le cancer du sein, des études prospectives ou au minimum rétrospectives sur des données issues d'études prospectives, sont nécessaires.

## SERMENT D'HIPPOCRATE

- *En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure, au nom de l'Être suprême, d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine.*
  
- *Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail.*
  
- *Admis (e) dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs, ni à favoriser le crime.*
  
- *Respectueux (se) et reconnaissant (e) envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.*
  
- *Que les hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert (e) d'opprobre et méprisé (e) de mes confrères si j'y manque.*



## Résumé

### Introduction :

Les marqueurs biologiques de l'inflammation (MBI) tels que le taux de leucocytes, lymphocytes, neutrophiles ou les ratios tels que les ratios de neutrophiles sur lymphocytes (NLR) ou plaquettes sur neutrophiles (PLR) émergent comment nouveaux facteurs pronostiques et prédictifs de réponse histologique complète ou de toxicité liée à la chimiothérapie (CT). De plus en plus d'études les ont évalués, avec des résultats divergents.

### Matériel et méthodes :

Nous avons réalisé une étude rétrospective sur 280 patientes suivies pour un cancer du sein localisé recevant une CT néoadjuvante. Les MBI avant traitement ont été recueillis ainsi que la réponse histologique, la survenue de toxicités, la récurrence et la survie.

Nous avons également réalisé une revue systématique de la littérature portant sur le NLR en tant que facteur pronostic et prédictif chez des patientes ayant un cancer du sein localisé (recevant une CT néoadjuvante d'une part et un traitement adjuvant d'autre part) ou métastatique.

### Résultats :

En analyse multivariée, un PLR élevé ( $\geq 150$ ) était corrélé à une moins bonne survie sans récurrence et survie globale (Hazard ratio [HR] = 1.91 ; IC95% = 1.15-3.16 ;  $p = 0.012$  et HR = 1.83 ; IC95% = 1.03-3.24 ;  $p = 0.039$ , respectivement). Le NLR était un facteur prédictif indépendant de neutropénie fébrile (Odds ratio = 0.28 ; IC95% = 0.13-0.58 ;  $p = 0,001$ ). Aucun MBI n'était prédictif de réponse histologique complète.

### Conclusion :

Le PLR est un facteur pronostic de survie dans notre population, alors que le NLR est un facteur prédictif de neutropénie fébrile. Ces résultats sont concordants avec ceux décrits dans notre revue de la littérature.

Mots clés : cancer du sein, marqueurs biologiques de l'inflammation, facteurs prédictifs, facteurs pronostiques, réponse histologique complète, toxicité liée à la chimiothérapie.